WO2016073774A2 - Immunoregulatory agents - Google Patents
Immunoregulatory agents Download PDFInfo
- Publication number
- WO2016073774A2 WO2016073774A2 PCT/US2015/059316 US2015059316W WO2016073774A2 WO 2016073774 A2 WO2016073774 A2 WO 2016073774A2 US 2015059316 W US2015059316 W US 2015059316W WO 2016073774 A2 WO2016073774 A2 WO 2016073774A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- compound
- formula
- optionally substituted
- ido
- Prior art date
Links
- 0 CC(CCNCC1)C1C(*)C(O*)=O Chemical compound CC(CCNCC1)C1C(*)C(O*)=O 0.000 description 5
- HOIGQKBFOGTUSW-QWQRMKEZSA-N C=CC[C@H]([C@H](CC1)CC[C@H]1c1c(cc(cc2)F)c2ncc1)N Chemical compound C=CC[C@H]([C@H](CC1)CC[C@H]1c1c(cc(cc2)F)c2ncc1)N HOIGQKBFOGTUSW-QWQRMKEZSA-N 0.000 description 1
- GIOFNJYZQDGWQL-KURKYZTESA-N CCOc1ccc(C(N[C@H](C)[C@H](CC2)CC[C@H]2c2c(cc(cc3)F)c3ncc2)=O)nc1 Chemical compound CCOc1ccc(C(N[C@H](C)[C@H](CC2)CC[C@H]2c2c(cc(cc3)F)c3ncc2)=O)nc1 GIOFNJYZQDGWQL-KURKYZTESA-N 0.000 description 1
- BNRCXLBTDMMGIP-IZAXUBKRSA-N Fc1cc2c([C@H](CC3)CC[C@H]3NCc3ccccc3)ccnc2cc1 Chemical compound Fc1cc2c([C@H](CC3)CC[C@H]3NCc3ccccc3)ccnc2cc1 BNRCXLBTDMMGIP-IZAXUBKRSA-N 0.000 description 1
- XFTBLPDJYOAEFP-UHFFFAOYSA-N O=C(Cc1cc(Cl)ccc1)NC1CCCCC1 Chemical compound O=C(Cc1cc(Cl)ccc1)NC1CCCCC1 XFTBLPDJYOAEFP-UHFFFAOYSA-N 0.000 description 1
- VQJNNDGKPYTFNR-CZIWCDLHSA-N O=C(N[C@H](CC1)CC[C@@H]1c1c(cc(cc2)F)c2ncc1)Nc(cc1)ccc1Cl Chemical compound O=C(N[C@H](CC1)CC[C@@H]1c1c(cc(cc2)F)c2ncc1)Nc(cc1)ccc1Cl VQJNNDGKPYTFNR-CZIWCDLHSA-N 0.000 description 1
- KLRLEPJKIXCIFM-CALCHBBNSA-N O=C([C@H]1CC[C@@H](Cc2ccccc2)CC1)Nc(cc1)ccc1F Chemical compound O=C([C@H]1CC[C@@H](Cc2ccccc2)CC1)Nc(cc1)ccc1F KLRLEPJKIXCIFM-CALCHBBNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/10—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Definitions
- IDO Indoleamine 2,3-dioxygenase
- IDOl is an IFN- ⁇ target gene that plays a role in immunomodulation.
- IDO is an oxidoreductase and one of two enzymes that catalyze the first and rate-limiting step in the conversion of tryptophan to N- formyl-kynurenine. It exists as a 41kD monomer that is found in several cell populations, including immune cells, endothelial cells, and fibroblasts. IDO is relatively well- conserved between species, with mouse and human sharing 63% sequence identity at the amino acid level.
- IDO plays a major role in immune regulation, and its immunosuppressive function manifests in several manners. Importantly, IDO regulates immunity at the T cell level, and a nexus exists between IDO and cytokine production. In addition, tumors frequently manipulate immune function by upregulation of IDO. Thus, modulation of IDO can have a therapeutic impact on a number of diseases, disorders and conditions.
- Treatment of cancer commonly entails surgical resection followed by chemotherapy and radiotherapy. The standard treatment regimens show highly variable degrees of long-term success because of the ability of tumor cells to essentially escape by regenerating primary tumor growth and, often more importantly, seeding distant metastasis.
- IDO In addition to cancer, IDO has been implicated in, among other conditions, immunosuppression, chronic infections, and autoimmune diseases or disorders (e.g. , rheumatoid arthritis). Thus, suppression of tryptophan degradation by inhibition of IDO activity has tremendous therapeutic value. Moreover, inhibitors of IDO can be used to enhance T cell activation when the T cells are suppressed by pregnancy, malignancy, or a virus (e.g., HIV). Although their roles are not as well defined, IDO inhibitors may also find use in the treatment of patients with neurological or neuropsychiatric diseases or disorders (e.g., depression).
- a virus e.g., HIV
- IDO inhibitors of IDO have been developed to treat or prevent IDO- related diseases.
- the IDO inhibitors 1-methyl-DL-tryptophan; p-(3- benzofuranyl)-DL-alanine; p-[3-benzo(b)thienyl]-DL-alanine; and 6-nitro-L-tryptophan have been used to modulate T cell-mediated immunity by altering local extracellular concentrations of tryptophan and tryptophan metabolites (WO 99/29310).
- Compounds having IDO inhibitory activity are further reported in PCT Publication No. WO
- the present invention relates to compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase (IDO), and compositions (e.g., pharmaceutical compositions) comprising the compounds.
- IDO indoleamine 2,3-dioxygenase
- compositions e.g., pharmaceutical compositions
- Such compounds including methods of their synthesis, and compositions are described in detail below.
- the present invention also relates to the use of such compounds and
- compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions mediated, in whole or in part, by IDO Such diseases, disorders and conditions are described in detail elsewhere herein. Unless otherwise indicated, when uses of the compounds of the present invention are described herein, it is to be understood that such compounds may be in the form of a composition (e.g., a pharmaceutical composition).
- IDO inhibitors encompasses compounds that act individually through inhibition of TDO or IDO, and/or compounds that act through inhibition of both IDO and TDO.
- the present invention provides compounds represented by formula
- n 1 or 0;
- A is -C(O)-, -NH-, -S0 2 -, -CH 2 -, or -CHR 3 -;
- B is a bond, -C(O)-, -NH-, -CH 2 -, or -CHR 3 -;
- T is a bond, -CH 2 -, -NH-, -0-, -OCH 2 -, -C(0)CH 2 -, or -CR 3 R 4 -;
- D is N or C(R 5 );
- E is N or C(R 6 );
- V is a bond, ⁇ O ⁇ , or ⁇ C(R 5a ) 2 ;
- G is an optionally substituted aryl, optionally substituted heteroaryl, or an optionally substituted 9 ⁇ or 10 ⁇ membered fused bicyclic heteroaryl;
- J 1 is CH, N or C(R 2 ), when R 2 is attached to the ring vertex identified as J 1 ;
- R 1 and R 2 are independently hydrogen, halogen, optionally substituted C 1 ⁇ C 4 haloalkyl, optionally substituted C 3 ⁇ C 6 cycloalkyl, optionally substituted 3 ⁇ to 6 ⁇ membered cycloheteroalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted C 1 ⁇ C 4 alkyl, optionally substituted C 1 ⁇ C 4 alkoxy, CN, SO 2 NH 2 , NHSO 2 CH 3 , NHSO 2 CF 3 , OCF 3 , SO 2 CH 3 , SO 2 CF 3 , or CONH 2 , and when R 1 and R 2 are on adjacent vertices of a phenyl ring they may be joined together to form a 5 ⁇ or 6 ⁇ membered cycloheteroalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said cycloheteroalkyl ring is optionally substituted with from
- R 3 and R 4 are independently hydrogen, optionally substituted C 1 ⁇ C 6 alkyl, optionally substituted C 1 ⁇ C 6 haloalkyl, fluorine, OH, CN, CO 2 H, C(O)NH 2 , N(R 5a ) 2 , optionally substituted ⁇ O ⁇ C 1 ⁇ C 6 alkyl, ⁇ (CR 5 R 5 ) m ⁇ OH, ⁇ (CR 5 R 5 ) m ⁇ CO 2 H,
- each R 5 is independently H, F, OH, optionally substituted C 1 ⁇ C 6 alkyl or optionally
- each R 5a is independently H, or optionally substituted C 1 ⁇ C 6 alkyl
- R 6 is H, OH, F, optionally substituted C 1 ⁇ C 6 alkyl, optionally substituted ⁇ O ⁇ C 1 ⁇ C 6 alkyl, or ⁇ N(R 5a ) 2 ;
- each m is independently 1, 2, or 3.
- the present invention provides compositions in which compounds of formula (I), are combined with one or more pharmaceutically acceptable excipients.
- the present invention contemplates methods for treating or preventing cancer in a subject (e.g., a human) comprising administering to the subject a therapeutically effective amount of at least one IDO inhibitor described herein.
- the present invention includes methods of treating or preventing a cancer in a subject by administering to the subject an IDO inhibitor in an amount effective to reverse or stop the progression of IDO-mediated immunosuppression.
- the IDO- mediated immunosuppression is mediated by an antigen-presenting cell (APC).
- APC antigen-presenting cell
- cancers that may be treated using the compounds and compositions described herein include, but are not limited to: cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin (including melanoma and basal carcinoma), mesothelial lining, white blood cell (including lymphoma and leukemia) esophagus, breast, muscle, connective tissue, lung (including small-cell lung carcinoma and non-small-cell carcinoma), adrenal gland, thyroid, kidney, or bone; glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.
- cancers of the prostate colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin (including melanoma
- the cancer is melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, a brain tumor, lymphoma, sarcoma, ovarian cancer, head and neck cancer, cervical cancer, or Kaposi's sarcoma. Cancers that are candidates for treatment with the compounds and compositions of the present invention are discussed further hereafter.
- the present invention contemplates methods of treating a subject receiving a bone marrow transplant or peripheral blood stem cell transplant by administering a therapeutically effective amount of an IDO inhibitor sufficient to increase the delayed- type hypersensitivity reaction to tumor antigen, delay the time-to-relapse of post- transplant malignancy, increase relapse-free survival time post-transplant, and/or increase long-term post-transplant survival.
- the present invention contemplates methods for treating or preventing an infective disorder (e.g., a viral infection) in a subject (e.g., a human) comprising administering to the subject a therapeutically effective amount of at least one IDO inhibitor (e.g., a novel inhibitor of the instant invention).
- an infective disorder e.g., a viral infection
- a subject e.g., a human
- the infective disorder is a viral infection (e.g., a chronic viral infection), a bacterial infection, or a parasitic infection.
- the viral infection is human
- the bacterial infection is a Mycobacterium infection (e.g. , Mycobacterium leprae or Mycobacterium tuberculosis).
- the parasitic infection is Leishmania donovani, Leishmania tropica, Leishmania major, Leishmania aethiopica, Leishmania mexicana, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae.
- the infective disorder is a fungal infection.
- the present invention contemplates methods for treating or preventing an immune-related disease, disorder or condition in a subject (e.g. , a human), comprising administering to the subject a therapeutically effective amount of at least one IDO inhibitor (e.g., preferably a novel inhibitor of the instant invention).
- a subject e.g. , a human
- at least one IDO inhibitor e.g., preferably a novel inhibitor of the instant invention
- the present invention further contemplates the use of the IDO inhibitors described herein in combination with one or more additional agents.
- the one or more additional agents may have some IDO modulating activity and/or they may function through distinct mechanisms of action.
- such agents comprise radiation (e.g., localized radiation therapy or total body radiation therapy) and/or other treatment modalities of a non-pharmacological nature.
- the IDO inhibitor(s) and the one additional agent(s) may be in the form of a single composition or multiple compositions, and the treatment modalities may be administered concurrently, sequentially, or through some other regimen.
- the present invention contemplates a treatment regimen wherein a radiation phase is followed by a chemotherapeutic phase.
- the combination therapy may have an additive or synergistic effect. Other benefits of combination therapy are described hereafter.
- the present invention further comprises the use of the IDO inhibitors described herein in combination with bone marrow transplantation, peripheral blood stem cell transplantation, or other types of transplantation therapy.
- the present invention contemplates the use of the inhibitors of IDO function described herein in combination with immune checkpoint inhibitors.
- the blockade of immune checkpoints which results in the amplification of antigen-specific T cell responses, has been shown to be a promising approach in human cancer therapeutics.
- immune checkpoints ligands and receptors
- PD1 programmed cell death protein 1
- PDL1 PD1 ligand
- BTLA B and T lymphocyte attenuator
- CTLA4 cytotoxic T-lymphocyte associated antigen 4
- TIM3 T-cell membrane protein 3
- LAG3 lymphocyte activation gene 3
- A2aR A2aR
- the present invention provides methods for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of at least one IDO inhibitor and at least one chemotherapeutic agent, such agents including, but not limited to alkylating agents (e.g., nitrogen mustards such as
- chlorambucil cyclophosphamide, isofamide, mechlorethamine, melphalan, and uracil mustard; aziridines such as thiotepa; methanesulphonate esters such as busulfan;
- nucleoside analogs e.g., gemcitabine
- nitroso ureas such as carmustine, lomustine, and streptozocin
- topoisomerase 1 inhibitors e.g. , irinotecan
- platinum complexes such as cisp latin and carbop latin
- bioreductive alkylators such as mitomycin, procarbazine, dacarbazine and altretamine
- DNA strand-breakage agents e.g., bleomycin
- topoisomerase II inhibitors e.g., amsacrine, dactinomycin, daunorubicin, idarubicin, mitoxantrone, doxorubicin, etoposide, and teniposide
- DNA minor groove binding agents e.g., plicamydin
- antimetabolites e.g., folate antagonists such as methotrexate and trimetrexate; pyrimidine antagonists such as fluorouracil, fluorodeoxyuridine, CB3717, azacitidine, cytarabine, and floxuridine; purine antagonists such as mercaptopurine, 6- thioguanine, fludarabine, pentostatin; asparginase; and ribonucleotide reductase inhibitors such as hydroxyurea); tubulin interactive agents (e.g., vincristine, estramustine, vinblastine, docetaxol, epoth
- the administration of a therapeutically effective amount of an IDO inhibitor in combination with at least one chemotherapeutic agent results in a cancer survival rate greater than the cancer survival rate observed by administering either alone.
- the administration of a therapeutically effective amount of an IDO inhibitor in combination with at least one chemotherapeutic agent results in a reduction of tumor size or a slowing of tumor growth greater than reduction of the tumor size or tumor growth observed by administration of one agent alone.
- the present invention contemplates methods for treating or preventing cancer in a subject, comprising administering to the subject a
- the at least one STI is selected from the group consisting of bcr/abl kinase inhibitors, epidermal growth factor (EGF) receptor inhibitors, her-2/neu receptor inhibitors, and farnesyl transferase inhibitors (FTIs).
- EGF epidermal growth factor
- FTIs farnesyl transferase inhibitors
- the present invention also contemplates methods of augmenting the rejection of tumor cells in a subject comprising administering an IDO inhibitor in conjunction with at least one chemotherapeutic agent and/or radiation therapy, wherein the resulting rejection of tumor cells is greater than that obtained by administering either the IDO inhibitor, the chemotherapeutic agent or the radiation therapy alone.
- the present invention provides methods for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of at least one IDO inhibitor and at least one immunomodulator other than an IDO inhibitor.
- the at least one immunomodulator is selected from the group consisting of CD40L, B7, B7RP1, ant-CD40, anti-CD38, anti-ICOS, 4- IBB ligand, dendritic cell cancer vaccine, IL2, IL12, ELC/CCL19, SLC/CCL21, MCP-1, IL-4, IL-18, TNF, IL-15, MDC, IFN- ⁇ /- ⁇ , M-CSF, IL-3, GM-CSF, IL-13, and anti-IL-10.
- the present invention contemplates embodiments comprising methods for treating or preventing an infective disorder (e.g., a viral infection) in a subject (e.g., a human) comprising administering to the subject a therapeutically effective amount of at least one IDO inhibitor and a therapeutically effective amount of an anti-infective agent(s)
- an infective disorder e.g., a viral infection
- a subject e.g., a human
- the additional therapeutic agent is a cytokine, including, for example, granulocyte-macrophage colony stimulating factor (GM-CSF) or flt3-ligand.
- a viral infection e.g., a chronic viral infection
- HCV hepatitis C virus
- HPV human papilloma virus
- CMV cytomegalovirus
- EBV Epstein-Barr virus
- varicella zoster virus coxsackie virus
- coxsackie virus and human
- HIV immunodeficiency virus
- treatment of an infective disorder is effected through the co-administration of a vaccine in combination with administration of a therapeutically effective amount of an IDO inhibitor of the present invention.
- the vaccine is an anti-viral vaccine, including, for example, an anti-HIV vaccine.
- the vaccine is effective against tuberculosis or malaria.
- the vaccine is a tumor vaccine (e.g., a vaccine effective against melanoma); the tumor vaccine may comprise genetically modified tumor cells or a genetically modified cell line, including genetically modified tumor cells or a genetically modified cell line that has been transfected to express granulocyte-macrophage stimulating factor (GM-CSF).
- the vaccine includes one or more immunogenic peptides and/or dendritic cells.
- the present invention contemplates methods of using the IDO inhibitors disclosed herein in combination with one or more antimicrobial agents.
- a symptom of infection observed after administering both the IDO inhibitor and the additional therapeutic agent is improved over the same symptom of infection observed after administering either alone.
- the symptom of infection observed may be reduction in viral load, increase in CD4 + T cell count, decrease in opportunistic infections, increased survival time, eradication of chronic infection, or a combination thereof.
- Figures 1A, 1B, 1C and 1D provide structures and biological activity for compounds described herein. DETAILED DESCRIPTION OF THE INVENTION
- Immune dysregulation is intimately associated with tumor evasion of the host immune system, resulting in tumor growth and progression.
- Traditional treatment approaches comprising chemotherapy and radiotherapy are generally difficult for the patient to tolerate and become less effective as tumors evolve to survive such treatments.
- immunotherapy has the benefit of reduced toxicity. As upregulation of the
- immunoregulatory enzyme indoleamine 2,3-dioxygenase comprises one mechanism manipulated by tumors to promote growth, agents (e.g., small molecule compounds) that inhibit enzyme activity present a promising avenue for prophylaxis and/or treatment.
- IDO inhibition in immunosuppression, tumor resistance and/or rejection, chronic infections, HIV- infection, and autoimmune diseases or disorders. Inhibition of IDO may also be an important treatment strategy for patients with neurological or neuropsychiatric diseases or disorders such as depression.
- the compounds, compositions and methods herein address the need for new classes of IDO modulators. Definitions
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (i.e., C 1 ⁇ 8 means one to eight carbons).
- alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n- pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- cycloalkyl refers to hydrocarbon rings having the indicated number of ring atoms (e.g., C 3 ⁇ 6 cycloalkyl) and being fully saturated or having no more than one double bond between ring vertices. "Cycloalkyl” is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2] octane, etc.
- cycloheteroalkyl refers to a cycloalkyl ring having the indicated number of ring vertices (or members) and having from one to five heteroatoms selected from N, O, and S, which replace one to five of the carbon vertices, and wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- the cycloheteroalkyl may be a monocyclic, a bicyclic or a polycyclic ring system.
- Non limiting examples of cycloheteroalkyl groups include pyrrolidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine,
- a cycloheteroalkyl group can be attached to the remainder of the molecule through a ring carbon or a heteroatom.
- a wavy line, “ ", that intersects a single, double or triple bond in any chemical structure depicted herein, represent the point attachment of the single, double, or triple bond to the remainder of the molecule.
- a bond extending to the center of a ring e.g., a phenyl ring
- a representation is meant to include either orientation (forward or reverse).
- ⁇ C(O)NH ⁇ is meant to include a linkage in either orientation: ⁇ C(O)NH ⁇ or ⁇ NHC(O) ⁇ , and similarly, " ⁇ O ⁇ CH 2 CH 2 ⁇ ” is meant to include both ⁇ O ⁇ CH 2 CH 2 ⁇ and ⁇ CH 2 CH 2 ⁇ O ⁇ .
- alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
- dialkylamino groups the alkyl portions can be the same or different and can also be combined to form a 3-7 membered ring with the nitrogen atom to which each is attached.
- a group represented as dialkylamino or ⁇ NR a R b is meant to include piperidinyl, pyrrolidinyl, morpholinyl, azetidinyl and the like.
- halo or "halogen", by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
- haloalkyl are meant to include monohaloalkyl and polyhaloalkyl.
- C 1 ⁇ 4 haloalkyl is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- aryl means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon group which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently.
- Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl.
- heteroaryl refers to aryl groups (or rings) that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
- Non- limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl,
- Optional substituents for the alkyl radicals can be a variety of groups selected from: halogen, ⁇ OR ⁇ , ⁇ NR ⁇ R ⁇ , ⁇ SR ⁇ , ⁇ SiR ⁇ R ⁇ R ⁇ , ⁇ OC(O)R ⁇ , ⁇ C(O)R ⁇ , ⁇ CO 2 R ⁇ , ⁇ CONR ⁇ R ⁇ , ⁇ OC(O)NR ⁇ R ⁇ , ⁇ NR ⁇ C(O)R ⁇ , ⁇ NR ⁇ C(O)NR ⁇ R ⁇ , ⁇ NR ⁇ C(O) 2 R ⁇ ,
- R ⁇ , R ⁇ and R ⁇ each independently refer to hydrogen, unsubstituted C 1 ⁇ 8 alkyl, unsubstituted aryl, aryl substituted with 1 ⁇ 3 halogens, unsubstituted C 1 ⁇ 8 alkyl, C 1 ⁇ 8 alkoxy or C 1 ⁇ 8 thioalkoxy groups, or unsubstituted aryl ⁇ C 1 ⁇ 4 alkyl groups.
- R ⁇ and R ⁇ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3 ⁇ , 4 ⁇ , 5 ⁇ , 6 ⁇ , or 7 ⁇ membered ring.
- ⁇ NR ⁇ R ⁇ is meant to include 1 ⁇ pyrrolidinyl and
- optional substituents for the aryl and heteroaryl groups are varied and are generally selected from: ⁇ halogen, ⁇ OR ⁇ , ⁇ OC(O)R ⁇ , ⁇ NR ⁇ R ⁇ , ⁇ SR ⁇ , ⁇ R ⁇ , ⁇ CN, ⁇ NO 2 , ⁇ CO 2 R ⁇ , ⁇ CONR ⁇ R ⁇ , ⁇ C(O)R ⁇ , ⁇ OC(O)NR ⁇ R ⁇ , ⁇ NR ⁇ C(O)R ⁇ , ⁇ NR ⁇ C(O) 2 R ⁇ ,
- R ⁇ , R ⁇ and R ⁇ are independently selected from hydrogen, C 1 ⁇ 8 alkyl, C 1 ⁇ 8 haloalkyl, C 3 ⁇ 6 cycloalkyl, C 2 ⁇ 8 alkenyl and C 2 ⁇ 8 alkynyl.
- R ⁇ , R ⁇ and R ⁇ are independently selected from hydrogen, C 1 ⁇ 8 alkyl, C 1 ⁇ 8 haloalkyl, C 3 ⁇ 6 cycloalkyl, C 2 ⁇ 8 alkenyl and C 2 ⁇ 8 alkynyl.
- Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1 ⁇ 4 carbon atoms.
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula ⁇ T ⁇ C(O) ⁇ (CH 2 ) q ⁇ U ⁇ , wherein T and U are independently ⁇ NH ⁇ , ⁇ O ⁇ , ⁇ CH 2 ⁇ or a single bond, and q is an integer of from 0 to 2.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula ⁇ A ⁇ (CH 2 ) r ⁇ B ⁇ , wherein A and B are independently ⁇ CH 2 ⁇ , ⁇ O ⁇ , ⁇ NH ⁇ , ⁇ S ⁇ , ⁇ S(O) ⁇ , ⁇ S(O) 2 ⁇ , ⁇ S(O) 2 NR ⁇ or a single bond, and r is an integer of from 1 to 3.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula ⁇ (CH 2 ) s ⁇ X ⁇ (CH 2 ) t ⁇ , where s and t are independently integers of from 0 to 3, and X is ⁇ O ⁇ , ⁇ NR ⁇ , ⁇ S ⁇ , ⁇ S(O) ⁇ , ⁇ S(O) 2 ⁇ , or ⁇ S(O) 2 NR ⁇ .
- the substituent R ⁇ in ⁇ NR ⁇ and ⁇ S(O) 2 NR ⁇ is selected from hydrogen or unsubstituted C 1 ⁇ 6 alkyl.
- heteroatom is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
- pharmaceutically acceptable salts is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like.
- Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N ⁇ -dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
- compounds of the present invention contain relatively basic
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- suitable inert solvent examples include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic,
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M. et al., "Pharmaceutical Salts", J. Pharm. Sci., 66:1-19 (1977)).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- the present invention provides compounds which are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
- prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, regioisomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention.
- a stereochemical depiction it is meant to refer the compound in which one of the isomers is present and substantially free of the other isomer.
- “Substantially free of" another isomer indicates at least an 80/20 ratio of the two isomers, more preferably 90/10, or 95/5 or more. In some embodiments, one of the isomers will be present in an amount of at least 99%.
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- Unnatural proportions of an isotope may be defined as ranging from the amount found in nature to an amount consisting of 100% of the atom in question.
- the compounds may incorporate radioactive isotopes, such as, for example, tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C), or non-radioactive isotopes, such as deuterium ( 2 H) or carbon-13 ( 13 C).
- radioactive isotopes such as, for example, tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C), or non-radioactive isotopes, such as deuterium ( 2 H) or carbon-13 ( 13 C).
- isotopic variations can provide additional utilities to those described elsewhere within this application.
- isotopic variants of the compounds of the invention may find additional utility, including but not limited to, as diagnostic and/or imaging reagents, or as cytotoxic/radiotoxic therapeutic agents.
- isotopic variants of the compounds of the invention can have altered pharmacokinetic and pharmacodynamic characteristics which can contribute to enhanced safety, tolerability or efficacy during treatment. All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
- patient or “subject” are used interchangeably to refer to a human or a non-human animal (e.g., a mammal).
- administer refers to contact of, for example, an inhibitor of IDO, a pharmaceutical composition comprising same, or a diagnostic agent to the subject, cell, tissue, organ, or biological fluid.
- an inhibitor of IDO a pharmaceutical composition comprising same
- a diagnostic agent a diagnostic agent to the subject, cell, tissue, organ, or biological fluid.
- administration includes contact (e.g., in vitro or ex vivo) of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
- treat refers to a course of action (such as administering an inhibitor of IDO or a pharmaceutical composition comprising same) initiated after a disease, disorder or condition, or a symptom thereof, has been diagnosed, observed, and the like so as to eliminate, reduce, suppress, mitigate, or ameliorate, either temporarily or permanently, at least one of the underlying causes of a disease, disorder, or condition afflicting a subject, or at least one of the symptoms associated with a disease, disorder, condition afflicting a subject.
- treatment includes inhibiting (e.g., arresting the development or further development of the disease, disorder or condition or clinical symptoms association therewith) an active disease.
- the term "in need of treatment” as used herein refers to a judgment made by a physician or other caregiver that a subject requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of the physician's or caregiver's expertise.
- prevent refers to a course of action (such as administering an IDO inhibitor or a pharmaceutical composition comprising same) initiated in a manner (e.g., prior to the onset of a disease, disorder, condition or symptom thereof) so as to prevent, suppress, inhibit or reduce, either temporarily or permanently, a subject's risk of developing a disease, disorder, condition or the like (as determined by, for example, the absence of clinical symptoms) or delaying the onset thereof, generally in the context of a subject predisposed to having a particular disease, disorder or condition.
- the terms also refer to slowing the progression of the disease, disorder or condition or inhibiting progression thereof to a harmful or otherwise undesired state.
- in need of prevention refers to a judgment made by a physician or other caregiver that a subject requires or will benefit from preventative care. This judgment is made based on a variety of factors that are in the realm of a physician's or caregiver's expertise.
- the phrase "therapeutically effective amount” refers to the administration of an agent to a subject, either alone or as part of a pharmaceutical composition and either in a single dose or as part of a series of doses, in an amount capable of having any detectable, positive effect on any symptom, aspect, or characteristic of a disease, disorder or condition when administered to the subject.
- the therapeutically effective amount can be ascertained by measuring relevant physiological effects, and it can be adjusted in connection with the dosing regimen and diagnostic analysis of the subject's condition, and the like.
- measurement of the serum level of and IDO inhibitor (or, e.g., a metabolite thereof) at a particular time post-administration may be indicative of whether a therapeutically effective amount has been used.
- the phrase "in a sufficient amount to effect a change” means that there is a detectable difference between a level of an indicator measured before (e.g., a baseline level) and after administration of a particular therapy.
- Indicators include any objective parameter (e.g., serum concentration) or subjective parameter (e.g., a subject's feeling of well-being).
- small molecules refers to chemical compounds having a molecular weight that is less than about 10kDa, less than about 2kDa, or less than about 1kDa.
- Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing an inorganic component, molecules comprising a radioactive atom, and synthetic molecules. Therapeutically, a small molecule may be more permeable to cells, less susceptible to degradation, and less likely to elicit an immune response than large molecules.
- IDO inhibitor As used herein, the terms "IDO inhibitor”, “IDO blocker” and terms similar thereto refer to agents capable of inhibiting the activity of IDO, thereby reversing IDO- mediated immunosuppression.
- An IDO inhibitor may be a competitive, noncompetitive, or irreversible IDO inhibitor.
- a competitive IDO inhibitor is a compound that reversibly inhibits IDO enzyme activity at the catalytic site;
- a noncompetitive IDO Inhibitor is a compound that reversibly inhibits IDO enzyme activity at a non-catalytic site; and
- an irreversible IDO inhibitor is a compound that irreversibly eliminates IDO enzyme activity by forming a covalent bond (or other stable means of inhibiting enzyme function) with the enzyme.
- a number of IDO inhibitors are commercially available (e.g., 5-Br-4-Cl-indoxyl 1,3-diacetate and 1-methyl-DL-tryptophan (1 MT); both available from Sigma-Aldrich, St. Louis, MO) and may be used as, for example, “tool” or
- ligand refers to, for example, a peptide, a polypeptide, a membrane- associated or membrane-bound molecule, or a complex thereof, that can act as an agonist or antagonist of a receptor.
- a ligand encompasses natural and synthetic ligands, e.g., cytokines, cytokine variants, analogs, muteins, and binding compositions derived from antibodies, as well as small molecules.
- the term also encompasses an agent that is neither an agonist nor antagonist, but that can bind to a receptor without significantly influencing its biological properties, e.g., signaling or adhesion.
- the term includes a membrane-bound ligand that has been changed by, e.g., chemical or recombinant methods, to a soluble version of the membrane-bound ligand.
- a ligand or receptor may be entirely intracellular, that is, it may reside in the cytosol, nucleus, or some other intracellular compartment.
- the complex of a ligand and receptor is termed a "ligand-receptor complex".
- inhibitors and “antagonists”, or “activators” and “agonists” refer to inhibitory or activating molecules, respectively, for example, for the activation of, e.g., a ligand, receptor, cofactor, gene, cell, tissue, or organ.
- Inhibitors are molecules that decrease, block, prevent, delay activation, inactivate, desensitize, or down-regulate, e.g., a gene, protein, ligand, receptor, or cell.
- Activators are molecules that increase, activate, facilitate, enhance activation, sensitize, or up-regulate, e.g., a gene, protein, ligand, receptor, or cell.
- An inhibitor may also be defined as a molecule that reduces, blocks, or inactivates a constitutive activity.
- An "agonist” is a molecule that interacts with a target to cause or promote an increase in the activation of the target.
- An "antagonist” is a molecule that opposes the action(s) of an agonist.
- An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist.
- modulate refers to the ability of a molecule (e.g., an activator or an inhibitor) to increase or decrease the function or activity of IDO, either directly or indirectly.
- a modulator may act alone, or it may use a cofactor, e.g., a protein, metal ion, or small molecule.
- modulators include small molecule compounds and other bioorganic molecules. Numerous libraries of small molecule compounds (e.g., combinatorial libraries) are commercially available and can serve as a starting point for identifying a modulator.
- the skilled artisan is able to develop one or more assays (e.g., biochemical or cell-based assays) in which such compound libraries can be screened in order to identify one or more compounds having the desired properties; thereafter, the skilled medicinal chemist is able to optimize such one or more compounds by, for example, synthesizing and evaluating analogs and derivatives thereof. Synthetic and/or molecular modeling studies can also be utilized in the identification of an Activator.
- assays e.g., biochemical or cell-based assays
- synthetic and/or molecular modeling studies can also be utilized in the identification of an Activator.
- the "activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the modulation of activities of other molecules; and the like.
- the term "proliferative activity” encompasses an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.
- “comparable”, “comparable activity”, “activity comparable to”, “comparable effect”, “effect comparable to”, and the like are relative terms that can be viewed quantitatively and/or qualitatively. The meaning of the terms is frequently dependent on the context in which they are used.
- two agents that both activate a receptor can be viewed as having a comparable effect from a qualitative perspective, but the two agents can be viewed as lacking a comparable effect from a quantitative perspective if one agent is only able to achieve 20% of the activity of the other agent as determined in an art-accepted assay (e.g., a dose-response assay) or in an art-accepted animal model.
- an art-accepted assay e.g., a dose-response assay
- “comparable” frequently means that one result deviates from a reference standard by less than 35%, by less than 30%, by less than 25%, by less than 20%, by less than 15%, by less than 10%, by less than 7%, by less than 5%, by less than 4%, by less than 3%, by less than 2%, or by less than 1%.
- one result is comparable to a reference standard if it deviates by less than 15%, by less than 10%, or by less than 5% from the reference standard.
- the activity or effect may refer to efficacy, stability, solubility, or immunogenicity.
- substantially pure indicates that a component makes up greater than about 50% of the total content of the composition, and typically greater than about 60% of the total polypeptide content. More typically, “substantially pure” refers to compositions in which at least 75%, at least 85%, at least 90% or more of the total composition is the component of interest. In some cases, the polypeptide will make up greater than about 90%, or greater than about 95% of the total content of the composition.
- a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample.
- the antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its antigen, or a variant or mutein thereof, with an affinity that is at least two-fold greater, at least ten times greater, at least 20-times greater, or at least 100-times greater than the affinity with any other antibody, or binding composition derived therefrom.
- the antibody will have an affinity that is greater than about 10 9 liters/mol, as determined by, e.g., Scatchard analysis (Munsen et al., Analyt. Biochem., 107:220-239 (1980)).
- response for example, of a cell, tissue, organ, or organism, encompasses a change in biochemical or physiological behavior, e.g., concentration, density, adhesion, or migration within a biological compartment, rate of gene expression, or state of differentiation, where the change is correlated with activation, stimulation, or treatment, or with internal mechanisms such as genetic programming.
- activation e.g., concentration, density, adhesion, or migration within a biological compartment, rate of gene expression, or state of differentiation
- activation e.g., concentration, density, adhesion, or migration within a biological compartment, rate of gene expression, or state of differentiation
- activation stimulation
- stimulation or treatment
- internal mechanisms such as genetic programming
- polypeptide refers to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified polypeptide backbones.
- the terms include fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusion proteins with heterologous and homologous leader sequences, with or without N-terminus methionine residues; immunologically tagged proteins; and the like.
- variants are used interchangeably to refer to amino acid or DNA sequences that are similar to reference amino acid or nucleic acid sequences, respectively.
- the term encompasses naturally-occurring variants and non-naturally-occurring variants.
- Naturally-occurring variants include homologs
- variants and homologs encompass naturally occurring DNA sequences and proteins encoded thereby and their isoforms, as well as splice variants of a protein or gene.
- the terms also encompass nucleic acid sequences that vary in one or more bases from a naturally-occurring DNA sequence but still translate into an amino acid sequence that corresponds to the naturally-occurring protein due to
- Non-naturally-occurring variants and homologs include polypeptides and nucleic acids that comprise a change in amino acid or nucleotide sequence, respectively, where the change in sequence is artificially introduced (e.g., muteins); for example, the change is generated in the laboratory by human intervention ("hand of man"). Therefore, non-naturally occurring variants and homologs may also refer to those that differ from the naturally-occurring sequences by one or more conservative substitutions and/or tags and/or conjugates.
- muteins refers broadly to mutated recombinant proteins. These proteins usually carry single or multiple amino acid substitutions and are frequently derived from cloned genes that have been subjected to site-directed or random mutagenesis, or from completely synthetic genes.
- DNA DNA
- nucleic acid nucleic acid molecule
- polynucleotide polynucleotide
- mRNA messenger RNA
- cDNA complementary DNA
- polynucleotides include linear and circular nucleic acids, messenger RNA (mRNA), complementary DNA (cDNA), recombinant polynucleotides, vectors, probes, primers and the like.
- mRNA messenger RNA
- cDNA complementary DNA
- IDO is an immune regulatory enzyme that is normally expressed in tumor cells and in activated immune cells. IDO is one of several immune response checkpoints that are involved in tumor immune escape; thus, IDO inhibitors disrupt mechanisms by which tumors evade the body's normal immune system.
- IDO down-regulates the immune response mediated through oxidation of tryptophan. This results in inhibition of T-cell activation and induction of T-cell apoptosis, creating an environment in which tumor-specific cytotoxic T lymphocytes are rendered functionally inactive or are no longer able to attack a subject's cancer cells. Therefore, therapeutic agents aimed at suppression of tryptophan degradation by inhibiting IDO activity are desirable.
- Inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibition of IDO may also be an important treatment strategy for patients with neurological or neuropsychiatric diseases or disorders such as depression. The compounds, compositions and methods herein help meet the current need for IDO modulators.
- IDO insulin glycoside deacetylases
- NF- ⁇ B signaling pathway has also been implicated in IDO function. Inhibiting NF- ⁇ B activity blocks IDO expression and produces robust anti-tumor responses that are both T cell- and IDO-dependent; alternatively, NF- ⁇ B activation (which may be effected by various factors such as interferon- ⁇ R1/- ⁇ R2 signaling and toll-like-receptor activation) induces IDO gene expression.
- inhibitors of reactive oxidative species may effect stabilization of IDO; IDO levels may be modulated by inhibition or activation of pathways that are both downstream and upstream of IDO; and activation of interferon- ⁇ can activate an autocrine induction of IDO.
- ROS reactive oxidative species
- IDO pathway is active in many cancers, both within tumor cells as a direct defense against T cell attack, and also within antigen-presenting cells (APCs) in tumor-draining lymph nodes resulting in peripheral tolerance to tumor- associated antigens (TAAs).
- APCs antigen-presenting cells
- TAAs tumor-associated antigens
- tryptophan catabolism in tumor tissue by the rate-limiting enzyme IDO provides an opportunity for the use of IDO inhibitors as a therapeutic alternative to, or an additive with, conventional chemotherapy.
- certain cancers are capable of catabolizing tryptophan but are largely IDO-negative.
- TDO tryptophan-2,3-dioxygenase
- TDO which is considered responsible for regulating systemic tryptophan levels in the liver, is constitutively expressed in some cancers and is also capable of suppressing antitumor immune responses (See, e.g., Platten, M. et al., Cancer Res., 72(21):5435-5440 (Nov.1, 2012)).
- IDO is expressed in a wide variety of human tumors and tumor cell lines as well as in host APCs, which correlates with a worse clinical prognosis. Therefore, inhibition of IDO may improve survival in cancer patients with IDO-mediated immunosuppression.
- TDO is expressed in a wide variety of human tumors and tumor cell lines, and expression of TDO is evident in advanced human glioblastomas.
- the identification of tumors expressing high levels of IDO or TDO may allow more selective inhibition of the tryptophan-regulated immunosuppressive pathways.
- compounds inhibiting both IDO and TDO could provide the greatest coverage to prevent tumor escape by compensatory expression of the other tryptophan-degrading enzyme.
- the compounds (or a subset thereof) are believed to inhibit IDO function.
- the compounds (or a subset thereof) may inhibit TDO function.
- the compounds (or a subset thereof) may also have inhibitory activity on both IDO and TDO function.
- the compounds of the invention are generally referred to herein as IDO inhibitors, it is to be understood that the term "IDO inhibitors" encompasses compounds that act individually through inhibition of TDO or IDO, and/or compounds that act through inhibition of both IDO and TDO. Identification of IDO Inhibitors Possessing Desirable Characteristics
- the present invention is drawn, in part, to the identification of inhibitors of IDO with at least one property or characteristic that is of therapeutic relevance.
- Candidate inhibitors may be identified by using, for example, an art-accepted assay or model, examples of which are described herein.
- candidate inhibitors can be further evaluated by using techniques that provide data regarding characteristics of the inhibitors (e.g.,
- n 1 or 0;
- A is ⁇ C(O) ⁇ , ⁇ NH ⁇ , ⁇ SO 2 ⁇ , ⁇ CH 2 ⁇ , or ⁇ CHR 3 ⁇ ;
- B is a bond, ⁇ C(O) ⁇ , ⁇ NH ⁇ , ⁇ CH 2 ⁇ , or ⁇ CHR 3 ⁇ ;
- T is a bond, ⁇ CH 2 ⁇ , ⁇ NH ⁇ , ⁇ O ⁇ , ⁇ OCH 2 ⁇ , ⁇ C(O)CH 2 ⁇ , or ⁇ CR 3 R 4 ⁇ ;
- T is other than ⁇ C(R 3 )(R 4 ) ⁇ ;
- D is N or C(R 5 );
- E is N or C(R 6 );
- V is a bond, ⁇ O ⁇ , or ⁇ C(R 5a ) 2 ;
- G is an optionally substituted aryl, optionally substituted heteroaryl, or an optionally substituted 9 ⁇ or 10 ⁇ membered fused bicyclic heteroaryl;
- J 1 is CH, N or C(R 2 ), when R 2 is attached to the ring vertex identified as J 1 ;
- R 1 and R 2 are independently hydrogen, halogen, optionally substituted C 1 ⁇ C 4 haloalkyl, optionally substituted C 3 ⁇ C 6 cycloalkyl, optionally substituted 3 ⁇ to 6 ⁇ membered cycloheteroalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted C 1 ⁇ C 4 alkyl, optionally substituted C 1 ⁇ C 4 alkoxy, CN, SO 2 NH 2 , NHSO 2 CH 3 , NHSO 2 CF 3 , OCF 3 , SO 2 CH 3 , SO 2 CF 3 , or CONH 2 , and when R 1 and R 2 are on adjacent vertices of a phenyl ring they may be joined together to form a 5 ⁇ or 6 ⁇ membered cycloheteroalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said cycloheteroalkyl ring is optionally substituted with from
- R 3 and R 4 are independently hydrogen, optionally substituted C 1 ⁇ C 6 alkyl, optionally substituted C 1 ⁇ C 6 haloalkyl, fluorine, OH, CN, CO 2 H, C(O)NH 2 , N(R 5a ) 2 , optionally substituted ⁇ O ⁇ C 1 ⁇ C 6 alkyl, ⁇ (CR 5 R 5 ) m ⁇ OH, ⁇ (CR 5 R 5 ) m ⁇ CO 2 H,
- each R 5 is independently H, F, OH, optionally substituted C 1 ⁇ C 6 alkyl or optionally substituted ⁇ O ⁇ C 1 ⁇ C 6 alkyl;
- each R 5a is independently H, or optionally substituted C 1 ⁇ C 6 alkyl
- R 6 is H, OH, F, optionally substituted C 1 ⁇ C 6 alkyl, optionally substituted ⁇ O ⁇ C 1 ⁇ C 6 alkyl, or ⁇ N(R 5a ) 2 ;
- each m is independently 1, 2, or 3.
- the com ounds rovided herein have the formula (Ia):
- the compounds provided herein have the formula (Ib), (Ic), or (Id):
- the compounds provided herein have the formula (Ie):
- the compounds provided herein have the formula (If), (Ig), or (Ih):
- the compounds provided herein have the formula (Ii) or (Ij):
- any one compound of Figure 1 is provided having an activity level identified as "A” or "B".
- any one compound of Figure 1 is provided having an activity level identified as "A”.
- the compounds of the present invention may be prepared from starting materials which are known in the chemical literature or are commercially available by methods such as those illustrated in the following Schemes utilizing chemical
- Ketones are deprotonated with bases such as LiHMDS and react with N-phenyltrifluoromethanesulfonimide or similar reagents to afford triflates of the general structure V.
- bases such as LiHMDS
- N-phenyltrifluoromethanesulfonimide or similar reagents to afford triflates of the general structure V.
- These triflates participate in Suzuki couplings (T. Ishiyama, M. Murata, N. Miyaura, J. Org. Chem., 1995, 60, 7508-7510) with boronic acids or esters G- B(OR) 2 to afford coupled products.
- Suzuki couplings T. Ishiyama, M. Murata, N. Miyaura, J. Org. Chem., 1995, 60, 7508-7510
- boronic acids or esters G- B(OR) 2 to afford coupled products.
- Many variations on this reaction are known, but generally it involves heating the two substrates and a
- reaction can be accomplished by activation of alcohol VII with DIAD, DEAD, or a related azodicarboxylate and a trialkyl or triarylphosphine and coupling with a phenol or related heteroaryl GOH.
- DIAD DIAD
- DEAD or a related azodicarboxylate
- a trialkyl or triarylphosphine and coupling with a phenol or related heteroaryl GOH.
- Intermediates VI (and later intermediates) may be obtained as mixtures of cis and trans isomers. Methods for control of the stereochemical outcome of the above reactions are known to those familiar in the art of organic/medicinal chemistry. Additionally, methods for the separation of these isomers are known and described in detail in the synthetic examples. If required, the group R 4 can be appended by alkylation of intermediate VI.
- Scheme 3 illustrates a method of making intermediate VI by performing the steps of Scheme 1 in a different order.
- Scheme 4 illustrates a method of making additional compounds of the invention.
- Ketone XII can be transformed into a nitrile by the use of TosMIC (Van Leusen reaction). Hydrolysis of the nitrile affords acid XIV which can be converted into compounds of the invention I by treatment with amines under amide coupling conditions.
- Scheme 5 ureas and phenylaceticamides of cyclohexylamine or 4-aminopiperidine, direct, C, or O-linked G
- Scheme 5 illustrates a method of making additional compounds of the invention.
- Ketones XII can be transformed into primary amines XV by reductive amination with ammonia or an ammonium salt. This reaction is generally performed using sodium cyanoborohydride in an alcoholic solvent. Treatment with isocyanates XVIc affords ureas which are compounds of the invention I.
- Arylacetamides which are compounds of the invention I are obtained by coupling amine XV with arylacetic acids XVId using a reagent such as Bop and a tertiary amine base in a solvent such as DMF.
- Scheme 6 Control of absolute stereochemistry in the conversion of VI to VIII
- Scheme 6 illustrates a method for controlling the absolute stereochemistry of intermediate VIII and materials arising from it.
- Saponification of esters VI provides carboxylic acids XVII.
- Treatment of these acids with an acid chloride such as pivaloyl chloride provides a mixed anhydride intermediate.
- an optically pure oxazolidinone of known stereochemistry and general structure XVIII is deprotonated by treatment with a strong base such as n-BuLi.
- bases such as NaHMDS.
- a ketone of general structure IV can be treated with a the lithiate G-Li, which can be generated by several methods well-known to one skilled in the art, to produce a tertiary alcohol of general structure XXI.
- the ester of general structure XXXI can be converted to a compound of general structure I via methods already described herein.
- the ketone IV can be treated with the
- the ester XXIII can be converted to a compound of the Invention (I) by methods already described herein.
- the compounds described herein can be prepared by representative methods as provided in the Examples below. Modifications to Enhance Inhibitor Characteristics
- the present invention contemplates the use of the IDO inhibitors described herein in the treatment or prevention of a broad range of diseases, disorders and/or conditions, and/or the symptoms thereof. While particular uses are described in detail hereafter, it is to be understood that the present invention is not so limited. Furthermore, although general categories of particular diseases, disorders and conditions are set forth hereafter, some of the diseases, disorders and conditions may be a member of more than one category, and others may not be a member of any of the disclosed categories.
- an IDO inhibitor can be used to treat or prevent a proliferative condition or disorder, including a cancer, for example, cancer of the uterus, cervix, breast, prostate, testes, gastrointestinal tract (e.g., esophagus, oropharynx, stomach, small or large intestines, colon, or rectum), kidney, renal cell, bladder, bone, bone marrow, skin, head or neck, liver, gall bladder, heart, lung, pancreas, salivary gland, adrenal gland, thyroid, brain (e.g., gliomas), ganglia, central nervous system (CNS) and peripheral nervous system (PNS), and cancers of the hematopoietic system and the immune system (e.g., spleen or thymus).
- a cancer for example, cancer of the uterus, cervix, breast, prostate, testes, gastrointestinal tract (e.g., esophagus, oropharynx, stomach, small or large intestine
- the present invention also provides methods of treating or preventing other cancer-related diseases, disorders or conditions, including, for example, immunogenic tumors, non-immunogenic tumors, dormant tumors, virus-induced cancers (e.g., epithelial cell cancers, endothelial cell cancers, squamous cell carcinomas and papillomavirus), adenocarcinomas, lymphomas, carcinomas, melanomas, leukemias, myelomas, sarcomas, teratocarcinomas, chemically-induced cancers, metastasis, and angiogenesis.
- immunogenic tumors e.g., epithelial cell cancers, endothelial cell cancers, squamous cell carcinomas and papillomavirus
- virus-induced cancers e.g., epithelial cell cancers, endothelial cell cancers, squamous cell carcinomas and papillomavirus
- the invention contemplates reducing tolerance to a tumor cell or cancer cell antigen, e.g., by modulating activity of a regulatory T-cell and/or a CD8+ T-cell (see, e.g., Ramirez-Montagut et al., Oncogene, 22:3180-3187 (2003); and Sawaya et al., New Engl. J. Med., 349:1501-1509 (2003)).
- the tumor or cancer is colon cancer, ovarian cancer, breast cancer, melanoma, lung cancer, glioblastoma, or leukemia.
- the use of the term(s) cancer- related diseases, disorders and conditions is meant to refer broadly to conditions that are associated, directly or indirectly, with cancer, and includes, e.g., angiogenesis and precancerous conditions such as dysplasia.
- the present invention provides methods for treating a proliferative condition, cancer, tumor, or precancerous condition with an IDO inhibitor and at least one additional therapeutic or diagnostic agent, examples of which are set forth elsewhere herein.
- Immune- and Inflammatory-related Disorders are meant to broadly encompass any immune- or inflammatory-related condition (e.g., pathological inflammation and autoimmune diseases). Such conditions frequently are inextricably intertwined with other diseases, disorders and conditions.
- an “immune condition” may refer to proliferative conditions, such as cancer, tumors, and angiogenesis; including infections (acute and chronic), tumors, and cancers that resist eradication by the immune system.
- a non-limiting list of immune- and inflammatory-related diseases, disorders and conditions which may be treated or prevented with the compounds and compositions of the present invention include, arthritis (e.g., rheumatoid arthritis), kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies, fibrosis, surgical complications (e.g., where inflammatory cytokines prevent healing), anemia, and fibromyalgia.
- Other diseases and disorders which may be associated with chronic inflammation include Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis,
- arteriosclerosis arteriosclerosis, osteoporosis, Parkinson's disease, infections, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), allergic contact dermatitis and other eczemas, systemic sclerosis, transplantation and multiple sclerosis.
- inflammatory bowel disease e.g., Crohn's disease and ulcerative colitis
- allergic contact dermatitis and other eczemas e.g., systemic sclerosis, transplantation and multiple sclerosis.
- IDO function may also play a role in immunologic tolerance and prevention of fetal rejection in utero.
- an IDO inhibitor described herein can be combined with an immunosuppressive agent to reduce the number of immune effector cells.
- an immunosuppressive agent to reduce the number of immune effector cells.
- RA Rheumatoid Arthritis
- DMARDs disease-modifying antirheumatic drugs
- ENBREL® etanercept
- REMICADE® infliximab
- HUMIRA® adalimumab
- KINERET® anakinra
- Psoriasis a constellation of common immune-mediated chronic skin diseases, affects more than 4.5 million people in the U.S., of which 1.5 million are considered to have a moderate-to severe form of the disease. Moreover, over 10% of patients with psoriasis develop psoriatic arthritis, which damages the bone and connective tissue around the joints.
- An improved understanding of the underlying physiology of psoriasis has resulted in the introduction of agents that, for example, target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of the disease.
- Such agents include the TNF- ⁇ inhibitors (also used in the treatment of rheumatoid arthritis (RA)), including ENBREL® (etanercept), REMICADE® (infliximab) and HUMIRA® (adalimumab)), and T-cell inhibitors such as AMEVIVE® (alefacept) and RAPTIVA® (efalizumab).
- RA rheumatoid arthritis
- ENBREL® etanercept
- REMICADE® infliximab
- HUMIRA® adalimumab
- AMEVIVE® alefacept
- RAPTIVA® efalizumab
- Subjects suffering from multiple sclerosis may be particularly helped by the IDO inhibitors described herein, as current treatments only alleviate symptoms or delay the progression of disability.
- the IDO inhibitors may be particularly advantageous for subjects afflicted with neurodegenerative disorders, such as Alzheimer's disease (AD), a brain disorder that seriously impairs patients' thought, memory, and language processes; and Parkinson's disease (PD), a progressive disorder of the CNS characterized by, for example, abnormal movement, rigidity and tremor. These disorders are progressive and debilitating, and no curative agents are available.
- AD Alzheimer's disease
- PD Parkinson's disease
- the present invention contemplates the use of the IDO inhibitors in the treatment and/or prevention of any viral disease, disorder or condition for which treatment with an IDO inhibitor may be beneficial.
- the viral disorder is a chronic viral disorder.
- viral diseases, disorders and conditions include, but are not limited to, hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), HIV, AIDS (including its manifestations such as cachexia, dementia, and diarrhea), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella zoster virus, coxsackie virus, and cytomegalovirus (CMV).
- Embodiments of the present invention contemplate the administration of the IDO inhibitors described herein to a subject for the treatment of a bacterial infection, for example, a Mycobacterium infection (e.g., Mycobacterium leprae or Mycobacterium tuberculosis) or an infection caused by Listeria monocytogenes or Toxplasma gondii.
- a Mycobacterium infection e.g., Mycobacterium leprae or Mycobacterium tuberculosis
- an infection caused by Listeria monocytogenes or Toxplasma gondii e.g., Mycobacterium leprae or Mycobacterium tuberculosis
- a parasitic infection including, but not limited to, Leishmania donovani, Leishmania tropica, Leishmania major, Leishmania aethiopica, Leishmania mexicana, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae.
- anti-parasitic therapy is administered prophylactically (e.g., before a subject travels to an area with a high frequency of parasitic infection).
- the IDO inhibitors of the present invention may be in the form of compositions suitable for administration to a subject.
- compositions suitable for administration to a subject.
- such compositions are
- compositions comprising an IDO inhibitor(s) and one or more pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients.
- the IDO inhibitors are present in a therapeutically acceptable amount.
- the pharmaceutical compositions may be used in the methods of the present invention; thus, for example, the pharmaceutical compositions can be administered ex vivo or in vivo to a subject in order to practice the therapeutic and prophylactic methods and uses described herein.
- compositions of the present invention can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein. Furthermore, the pharmaceutical compositions may be used in combination with other therapeutically active agents or compounds as described herein in order to treat or prevent the diseases, disorders and conditions as contemplated by the present invention.
- compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads or elixirs.
- compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents such as, for example, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide
- Tablets, capsules and the like contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
- the tablets, capsules and the like suitable for oral administration may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action.
- a time-delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by techniques known in the art to form osmotic therapeutic tablets for controlled release.
- Additional agents include biodegradable or biocompatible particles or a polymeric substance such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides, polyglycolic acid, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers,
- the oral agent can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, by the use of hydroxymethylcellulose or gelatin-microcapsules or poly (methylmethacrolate) microcapsules, respectively, or in a colloid drug delivery system.
- Colloidal dispersion systems include macromolecule complexes, nano-capsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the above-mentioned formulations will be apparent to those skilled in the art.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, kaolin or microcrystalline cellulose, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate, kaolin or microcrystalline cellulose
- water or an oil medium for example, peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture thereof.
- excipients can be suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example, a naturally-occurring phosphatide (e.g., lecithin), or condensation products of an alkylene oxide with fatty acids (e.g., polyoxy- ethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., for heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, ka
- compositions of the present invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin, or mixtures of these.
- Suitable emulsifying agents may be naturally occurring gums, for example, gum acacia or gum tragacanth; naturally occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids; hexitol anhydrides, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
- Formulations can also include carriers to protect the composition against rapid degradation or elimination from the body, such as a controlled release formulation, including implants, liposomes, hydrogels, prodrugs and microencapsulated delivery systems.
- a time delay material such as glyceryl monostearate or glyceryl stearate alone, or in combination with a wax, may be employed.
- compositions typically comprise a therapeutically effective amount of an IDO inhibitor contemplated by the present invention and one or more pharmaceutically and physiologically acceptable formulation agents.
- pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients include, but are not limited to, antioxidants (e.g., ascorbic acid and sodium bisulfate), preservatives (e.g., benzyl alcohol, methyl parabens, ethyl or n-propyl, p- hydroxybenzoate), emulsifying agents, suspending agents, dispersing agents, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents, and/or adjuvants.
- a suitable vehicle may be physiological saline solution or citrate buffered saline, possibly supplemented with other materials common in pharmaceutical compositions for parenteral administration.
- Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles.
- Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof.
- the buffer components can be water soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof.
- Acceptable buffering agents include, for example, a Tris buffer, N-(2- hydroxyethyl)piperazine-N ⁇ -(2-ethanesulfonic acid) (HEPES), 2-(N-morpholino) ethanesulfonic acid (MES), 2-(N-morpholino)ethanesulfonic acid sodium salt (MES), 3- (N-morpholino)propanesulfonic acid (MOPS), and N-tris[hydroxymethyl]methyl-3- aminopropanesulfonic acid (TAPS).
- HEPES N-(2- hydroxyethyl)piperazine-N ⁇ -(2-ethanesulfonic acid)
- MES 2-(N-morpholino) ethanesulfonic acid
- MES 2-(N-morpholino)ethanesulfonic acid sodium salt
- MOPS 3- (N-morpholino)propanesulfonic acid
- TAPS N-tris[hydroxymethyl]methyl-3- aminopropanesulfonic acid
- a pharmaceutical composition After a pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form, a lyophilized form requiring reconstitution prior to use, a liquid form requiring dilution prior to use, or other acceptable form.
- the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, ampoule, syringe, or
- any drug delivery apparatus may be used to deliver and IDO inhibitor, including implants (e.g., implantable pumps) and catheter systems, slow injection pumps and devices, all of which are well known to the skilled artisan. Depot injections, which are generally administered subcutaneously or
- Depot injections are usually either solid- or oil-based and generally comprise at least one of the formulation components set forth herein.
- One of ordinary skill in the art is familiar with possible formulations and uses of depot injections.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents mentioned herein.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol.
- Acceptable diluents, solvents and dispersion media include water, Ringer's solution, isotonic sodium chloride solution, CREMOPHOR® EL (BASF, Parsippany, NJ) or phosphate buffered saline (PBS), ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed, including synthetic mono- or diglycerides.
- fatty acids such as oleic acid, find use in the preparation of injectables. Prolonged absorption of particular injectable formulations can be achieved by including an agent that delays absorption (e.g., aluminum monostearate or gelatin).
- the present invention contemplates the administration of the IDO inhibitors in the form of suppositories for rectal administration.
- the suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include, but are not limited to, cocoa butter and polyethylene glycols.
- the IDO inhibitors contemplated by the present invention may be in the form of any other suitable pharmaceutical composition (e.g., sprays for nasal or inhalation use) currently known or developed in the future.
- suitable pharmaceutical composition e.g., sprays for nasal or inhalation use
- concentration of a polypeptide or fragment thereof in a formulation can vary widely (e.g., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight) and will usually be selected primarily based on fluid volumes, viscosities, and subject-based factors in accordance with, for example, the particular mode of administration selected.
- Routes of Administration e.g., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight
- the present invention contemplates the administration of IDO inhibitors, and compositions thereof, in any appropriate manner.
- Suitable routes of administration include oral, parenteral (e.g., intramuscular, intravenous, subcutaneous (e.g., injection or implant), intraperitoneal, intracisternal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intracerebroventricular), nasal, vaginal, sublingual, intraocular, rectal, topical (e.g., transdermal), sublingual and inhalation.
- Depot injections which are generally administered subcutaneously or intramuscularly, may also be utilized to release the IDO inhibitors disclosed herein over a defined period of time.
- Particular embodiments of the present invention contemplate oral
- the present invention contemplates the use of IDO inhibitors in combination with one or more active therapeutic agents (e.g., chemotherapeutic agents) or other prophylactic or therapeutic modalities (e.g., radiation).
- active therapeutic agents e.g., chemotherapeutic agents
- prophylactic or therapeutic modalities e.g., radiation
- the various active agents frequently have different, complementary mechanisms of action.
- Such combination therapy may be especially advantageous by allowing a dose reduction of one or more of the agents, thereby reducing or eliminating the adverse effects associated with one or more of the agents.
- such combination therapy may have a synergistic therapeutic or prophylactic effect on the underlying disease, disorder, or condition.
- kits therapies that can be administered separately, for example, formulated separately for separate administration (e.g., as may be provided in a kit), and therapies that can be administered together in a single formulation (i.e., a "co-formulation").
- the IDO inhibitors are administered or applied sequentially, e.g., where one agent is administered prior to one or more other agents.
- the IDO inhibitors are administered simultaneously, e.g., where two or more agents are administered at or about the same time; the two or more agents may be present in two or more separate formulations or combined into a single formulation (i.e., a co-formulation). Regardless of whether the two or more agents are administered sequentially or simultaneously, they are considered to be administered in combination for purposes of the present invention.
- the IDO inhibitors of the present invention may be used in combination with at least one other (active) agent in any manner appropriate under the circumstances.
- treatment with the at least one active agent and at least one IDO inhibitor of the present invention is maintained over a period of time.
- treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), while treatment with an IDO inhibitor of the present invention is maintained at a constant dosing regimen.
- treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), while treatment with an IDO inhibitor of the present invention is reduced (e.g., lower dose, less frequent dosing or shorter treatment regimen).
- treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), and treatment with the IDO inhibitor of the present invention is increased (e.g., higher dose, more frequent dosing or longer treatment regimen).
- treatment with the at least one active agent is maintained and treatment with the IDO inhibitor of the present invention is reduced or discontinued (e.g., lower dose, less frequent dosing or shorter treatment regimen).
- treatment with the at least one active agent and treatment with the IDO inhibitor of the present invention are reduced or discontinued (e.g., lower dose, less frequent dosing or shorter treatment regimen).
- the present invention provides methods for treating and/or preventing a proliferative condition, cancer, tumor, or precancerous disease, disorder or condition with an IDO inhibitor and at least one additional therapeutic agent, such as radiation, an immunomodulatory agent or chemotherapeutic agent, or diagnostic agent.
- Suitable immunomodulatory agents include CD40L, B7, and B7RP1; activating monoclonal antibodies (mAbs) to stimulatory receptors, such as, ant-CD40, anti-CD38, anti-ICOS, and 4-IBB ligand;
- dendritic cell antigen loading in vitro or in vivo
- anti-cancer vaccines such as dendritic cell cancer vaccines
- cytokines/chemokines such as, IL1, IL2, IL12, IL18, ELC/CCL19, SLC/CCL21, MCP-1, IL-4, IL-18, TNF, IL-15, MDC, IFNa/b, M-CSF, IL-3, GM-CSF, IL-13, and anti-IL-10
- bacterial lipopolysaccharides LPS
- immune-stimulatory oligonucleotides such as, IL1, IL2, IL12, IL18, ELC/CCL19, SLC/CCL21, MCP-1, IL-4, IL-18, TNF, IL-15, MDC, IFNa/b, M-CSF, IL-3, GM-CSF, IL-13, and anti-IL-10
- LPS bacterial lipopolysaccharides
- chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine,
- folic acid replenisher such as frolinic acid
- aceglatone aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; urethan; vindesine; dacarbazine;
- mannomustine mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (Ara-C); cyclophosphamide; thiotepa; taxoids, e.g., paclitaxel and doxetaxel; chlorambucil;
- gemcitabine 6-thioguanine; mercaptopurine; methotrexate; platinum and platinum coordination complexes such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT11; topoisomerase inhibitors; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
- VP-16 etoposide
- ifosfamide mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin;
- Chemotherapeutic agents also include anti-hormonal agents that act to regulate or inhibit hormonal action on tumors such as anti-estrogens, including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, onapristone, and toremifene; and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
- combination therapy comprises administration of a hormone or related hormonal agent.
- STI signal transduction inhibitors
- bcr/abl kinase inhibitors e.g., GLEEVEC
- EGF epidermal growth factor
- EGF epidermal growth factor
- her-2/neu receptor inhibitors e.g., HERCEPTIN
- inhibitors of Akt family kinases or the Akt pathway e.g., rapamycin
- cell cycle kinase inhibitors e.g., flavopiridol
- phosphatidyl inositol kinase inhibitors phosphatidyl inositol kinase inhibitors.
- Additional treatment modalities that may be used in combination with an IDO inhibitor include a cytokine or cytokine antagonist, such as IL-12, IFN, or anti-epidermal growth factor receptor, radiotherapy, a monoclonal antibody against another tumor antigen, a complex of a monoclonal antibody and toxin, a T-cell adjuvant, bone marrow transplant, or antigen presenting cells (e.g., dendritic cell therapy).
- Vaccines e.g., as a soluble protein or as a nucleic acid encoding the protein are also provided herein.
- Cardiovascular Diseases e.g., as a soluble protein or as a nucleic acid encoding the protein.
- the present invention provides methods for treating and/or preventing certain cardiovascular- and/or metabolic-related diseases, disorders and conditions, as well as disorders associated therewith, with an IDO inhibitor and at least one additional therapeutic or diagnostic agent.
- therapeutic agents useful in combination therapy for the treatment of hypercholesterolemia include statins (e.g., CRESTOR, LESCOL, LIPITOR, MEVACOR, PRAVACOL, and ZOCOR), which inhibit the enzymatic synthesis of cholesterol; bile acid resins (e.g., COLESTID, LO-CHOLEST, PREVALITE, QUESTRAN, and WELCHOL), which sequester cholesterol and prevent its absorption; ezetimibe (ZETIA), which blocks cholesterol absorption; fibric acid (e.g., TRICOR), which reduces triglycerides and may modestly increase HDL; niacin (e.g., NIACOR), which modestly lowers LDL cholesterol and triglycer
- statins e.g., C
- Alternative cholesterol treatments that may be candidates for use in combination with the IDO inhibitors described herein include various supplements and herbs (e.g., garlic, policosanol, and guggul).
- the present invention encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.
- Immune- and Inflammatory-related Disorders The present invention provides methods for treating and/or preventing immune- and/or inflammatory-related diseases, disorders and conditions, as well as disorders associated therewith, with an IDO inhibitor and at least one additional therapeutic or diagnostic agent.
- Examples of therapeutic agents useful in combination therapy include, but are not limited to, the following: non-steroidal anti-inflammatory drug (NSAID) such as aspirin, ibuprofen, and other propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, fuirofenac, ibufenac, isox
- ком ⁇ онентs for combination include steroids such as prednisolone, prednisone, methylprednisolone, betamethasone, dexamethasone, or hydrocortisone. Such a combination may be especially advantageous since one or more adverse effects of the steroid can be reduced or even eliminated by tapering the steroid dose required.
- active agents include cytokine suppressive anti- inflammatory drug(s) (CSAIDs); antibodies to, or antagonists of, other human cytokines or growth factors, for example, TNF, LT, IL-1 ⁇ , IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL- 18, EMAP-II, GM-CSF, FGF, or PDGF.
- CSAIDs cytokine suppressive anti- inflammatory drug
- TNF antagonists such as chimeric, humanized or human TNF antibodies, REMICADE, anti-TNF antibody fragments (e.g., CDP870), and soluble p55 or p75 TNF receptors, derivatives thereof, p75TNFRIgG (ENBREL.) or p55TNFR1gG (LENERCEPT), soluble IL-13 receptor (sIL- 13), and also TNF ⁇ -converting enzyme (TACE) inhibitors; similarly, IL-1 inhibitors (e.g., Interleukin-1-converting enzyme inhibitors) may be effective.
- TNF antagonists such as chimeric, humanized or human TNF antibodies, REMICADE, anti-TNF antibody fragments (e.g., CDP870), and soluble p55 or p75 TNF receptors, derivatives thereof, p75TNFRIgG (ENBREL.) or p55TNFR1gG (LENERCEPT), soluble IL-13 receptor (sIL- 13), and also TNF ⁇ -converting enzyme (TACE
- Interleukin 11 anti-P7s and p-selectin glycoprotein ligand (PSGL).
- agents useful in combination with the IDO inhibitors described herein include interferon- ⁇ 1a (AVONEX); interferon- ⁇ 1b (BETASERON); copaxone;
- Immune Checkpoint Inhibitors The present invention contemplates the use of the inhibitors of IDO function described herein in combination with additional immune checkpoint inhibitors.
- T cells T-cell receptor
- the ultimate amplitude (e.g., levels of cytokine production or proliferation) and quality (e.g., the type of immune response generated, such as the pattern of cytokine production) of the response, which is initiated through antigen recognition by the T-cell receptor (TCR) is regulated by a balance between co-stimulatory and inhibitory signals (immune
- immune checkpoints Under normal physiological conditions, immune checkpoints are crucial for the prevention of autoimmunity (i.e., the maintenance of self-tolerance) and also for the protection of tissues from damage when the immune system is responding to pathogenic infection.
- autoimmunity i.e., the maintenance of self-tolerance
- the expression of immune checkpoint proteins can be dysregulated by tumors as an important immune resistance mechanism.
- T cells have been the major focus of efforts to therapeutically manipulate endogenous antitumor immunity because of i) their capacity for the selective recognition of peptides derived from proteins in all cellular compartments; ii) their capacity to directly recognize and kill antigen-expressing cells (by CD8+ effector T cells; also known as cytotoxic T lymphocytes (CTLs)); and iii) their ability to orchestrate diverse immune responses by CD4+ helper T cells, which integrate adaptive and innate effector mechanisms.
- CTLs cytotoxic T lymphocytes
- T cell-mediated immunity includes multiple sequential steps, each of which is regulated by counterbalancing stimulatory and inhibitory signals in order to optimize the response. While nearly all inhibitory signals in the immune response ultimately modulate intracellular signaling pathways, many are initiated through membrane receptors, the ligands of which are either membrane-bound or soluble (cytokines). While co- stimulatory and inhibitory receptors and ligands that regulate T-cell activation are frequently not over-expressed in cancers relative to normal tissues, inhibitory ligands and receptors that regulate T cell effector functions in tissues are commonly overexpressed on tumor cells or on non-transformed cells associated with the tumor microenvironment.
- the functions of the soluble and membrane-bound receptor– ligand immune checkpoints can be modulated using agonist antibodies (for co-stimulatory pathways) or antagonist antibodies (for inhibitory pathways).
- agonist antibodies for co-stimulatory pathways
- antagonist antibodies for inhibitory pathways.
- antibodies that block immune checkpoints do not target tumor cells directly, but rather target lymphocyte receptors or their ligands in order to enhance endogenous antitumor activity. [See Pardoll, (April 2012) Nature Rev. Cancer 12:252-64].
- immune checkpoints ligands and receptors
- PD1 programmed cell death protein 1
- PDL1 PD1 ligand
- BTLA B and T lymphocyte attenuator
- CTLA4 cytotoxic T-lymphocyte associated antigen 4
- TIM3 T-cell membrane protein 3
- LAG3 lymphocyte activation gene 3
- A2aR adenosine A2a receptor A2aR
- Killer Inhibitory Receptors which can be divided into two classes based on their structural features: i) killer cell immunoglobulin-like receptors (KIRs), and ii) C-type lectin receptors (members of the type II transmembrane receptor family).
- KIRs killer cell immunoglobulin-like receptors
- C-type lectin receptors members of the type II transmembrane receptor family
- immune checkpoints include both receptors (e.g., the 2B4 (also known as CD244) receptor) and ligands (e.g., certain B7 family inhibitory ligands such B7-H3 (also known as CD276) and B7-H4 (also known as B7-S1, B7x and VCTN1)).
- B7-H3 also known as CD276
- B7-H4 also known as B7-S1, B7x and VCTN1
- the present invention contemplates the use of the inhibitors of IDO function described herein in combination with inhibitors of the aforementioned immune- checkpoint receptors and ligands, as well as yet-to-be-described immune-checkpoint receptors and ligands.
- PD1 antibodies are also available for the treatment of cancer, including for example nivolumab (Bristol-Myers Squibb) and pembroluzimab (Merck), and anti-PDL1 antibodies are also being evaluated (e.g., MPDL3280A (Roche)).
- Nivolumab (Opdivo®) has shown promise in patients with melanoma, lung and kidney cancer, as well as multiple other malignancies.
- the claimed IDO inhibitors are combined with an immuno-oncology agent that is (i) an agonist of a stimulatory (including a co- stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co-inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses.
- an immuno-oncology agent that is (i) an agonist of a stimulatory (including a co- stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co-inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses.
- Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF).
- B7 family which includes B7-1, B7-2, B7- H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6.
- TNF family of molecules that bind to cognate TNF receptor family members which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4,
- TRAILR2/DR5, TRAILR3, TRAILR4, OPG RANK, RANKL, TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LT ⁇ R, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1,
- the immuno-oncology agent is a cytokine that inhibits T cell activation (e.g., IL-6, IL-10, TGF-ß, VEGF, and other immunosuppressive cytokines) or a cytokine that stimulates T cell activation, for stimulating an immune response.
- T cell activation e.g., IL-6, IL-10, TGF-ß, VEGF, and other immunosuppressive cytokines
- a cytokine that stimulates T cell activation for stimulating an immune response.
- T cell responses can be stimulated by a combination of the claimed IDO inhibitors and one or more of (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD- L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4, and/or (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD2.
- an antagonist of a protein that inhibits T cell activation e.g., immune checkpoint inhibitor
- agents that can be combined with the IDO inhibitors of the present invention for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells.
- compounds herein can be combined with antagonists of KIR, such as lirilumab.
- agents for combination therapies include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WO11/70024, WO11/107553, WO11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008
- the claimed IDO inhibitors can be used with one or more of agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L1/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
- agonistic agents that ligate positive costimulatory receptors e.g., blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells
- the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonistic CTLA-4 antibody.
- Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.
- the immuno-oncology agent is a PD-1 antagonist, such as an antagonistic PD-1 antibody.
- Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab/lambrolizumab), or MEDI-0680 (AMP-514; WO2012/145493).
- the immuno-oncology agent may also include pidilizumab (CT-011), though its specificity for PD-1 binding has been questioned.
- CT-011 pidilizumab
- Another approach to target the PD-1 receptor is the recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgG1, called AMP-224
- the immuno-oncology agent is a PD-L1 antagonist, such as an antagonistic PD-L1 antibody.
- Suitable PD-L1 antibodies include, for example,
- the immuno-oncology agent is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody.
- LAG3 antibodies include, for example, BMS- 986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601,
- the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody.
- Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (WO12/32433).
- the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody.
- Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06/105021, WO09/009116) and MK-4166 (WO11/028683).
- the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody. Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469. [0183] In another aspect, the immuno-oncology agent is an OX40L antagonist, such as an antagonistic OX40 antibody. Suitable OX40L antagonists include, for example, RG- 7888 (WO06/029879). [0184] In another aspect, the immuno-oncology agent is a CD40 agonist, such as an agonistic CD40 antibody. In yet another embodiment, the immuno-oncology agent is a CD40 antagonist, such as an antagonistic CD40 antibody.
- Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab.
- the immuno-oncology agent is a CD27 agonist, such as an agonistic CD27 antibody.
- Suitable CD27 antibodies include, for example, varlilumab.
- the immuno-oncology agent is MGA271 (to B7H3)
- the present invention encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.
- Viral Diseases The present invention provides methods for treating and/or preventing viral diseases, disorders and conditions, as well as disorders associated therewith, with an IDO inhibitor and at least one additional therapeutic or diagnostic agent (e.g., one or more other antiviral agents and/or one or more agents not associated with viral therapy).
- Such combination therapy includes anti-viral agents targeting various viral life- cycle stages and having different mechanisms of action, including, but not limiting to, the following: inhibitors of viral uncoating (e.g., amantadine and rimantidine); reverse transcriptase inhibitors (e.g., acyclovir, zidovudine, and lamivudine); agents that target integrase; agents that block attachment of transcription factors to viral DNA; agents (e.g., antisense molecules) that impact translation (e.g., fomivirsen); agents that modulate translation/ribozyme function; protease inhibitors; viral assembly modulators (e.g., rifampicin); antiretrovirals such as, for example, nucleoside analogue reverse
- transcriptase inhibitors e.g., azidothymidine (AZT), ddl, ddC, 3TC, d4T
- non-nucleoside reverse transcriptase inhibitors e.g., efavirenz, nevirapine
- nucleotide analogue reverse transcriptase inhibitors e.g., zanamivir and oseltamivir
- Treatment and/or prevention of certain viral infections e.g., HIV
- HIV frequently entail a group (“cocktail”) of antiviral agents.
- antiviral agents contemplated for use in combination with an IDO inhibitor include, but are not limited to, the following: abacavir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevirertet, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, various interferons (e.g., peginterferon alfa-2a), lopinavir, loviride, maraviroc, moroxydine, methisazone,
- the present invention encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.
- Parasitic Disorders contemplates the use of the inhibitors of IDO function described herein in combination with antiparasitic agents.
- agents include, but are not limited to, thiabendazole, pyrantel pamoate, mebendazole, praziquantel, niclosamide, bithionol, oxamniquine, metrifonate, ivermectin, albendazole, eflornithine, melarsoprol, pentamidine, benznidazole, nifurtimox, and nitroimidazole.
- the skilled artisan is aware of other agents that may find utility for the treatment of parasitic disorders.
- the present invention encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.
- Bacterial Infections Embodiments of the present invention contemplate the use of the IDO inhibitors described herein in combination with agents useful in the treatment or prevention of bacterial disorders.
- Antibacterial agents can be classified in various manners, including based on mechanism of action, based on chemical structure, and based on spectrum of activity.
- antibacterial agents examples include those that target the bacterial cell wall (e.g., cephalosporins and penicillins) or the cell membrane (e.g., polymyxins), or interfere with essential bacterial enzymes (e.g., sulfonamides, rifamycins, and quinolines).
- Most antibacterial agents that target protein synthesis e.g., tetracyclines and macrolides
- agents such as the aminoglycoside are bactericidal.
- antibacterial agents Another means of categorizing antibacterial agents is based on their target specificity;“narrow-spectrum” agents target specific types of bacteria (e.g., Gram- positive bacteria such as Streptococcus), while“broad-spectrum” agents have activity against a broader range of bacteria.
- “narrow-spectrum” agents target specific types of bacteria (e.g., Gram- positive bacteria such as Streptococcus)
- “broad-spectrum” agents have activity against a broader range of bacteria.
- the skilled artisan is aware of types of anti-bacterial agents that are appropriate for use in specific bacterial infections.
- the present invention encompasses pharmaceutically acceptable salts, acids or derivatives of the agents (and members of the classes of agents) set forth above. Dosing
- the IDO inhibitors of the present invention may be administered to a subject in an amount that is dependent upon, for example, the goal of administration (e.g., the degree of resolution desired); the age, weight, sex, and health and physical condition of the subject to which the formulation is being administered; the route of administration; and the nature of the disease, disorder, condition or symptom thereof.
- the dosing regimen may also take into consideration the existence, nature, and extent of any adverse effects associated with the agent(s) being administered. Effective dosage amounts and dosage regimens can readily be determined from, for example, safety and dose-escalation trials, in vivo studies (e.g., animal models), and other methods known to the skilled artisan.
- dosing parameters dictate that the dosage amount be less than an amount that could be irreversibly toxic to the subject (the maximum tolerated dose (MTD)) and not less than an amount required to produce a measurable effect on the subject.
- MTD maximum tolerated dose
- Such amounts are determined by, for example, the pharmacokinetic and pharmacodynamic parameters associated with ADME, taking into consideration the route of administration and other factors.
- An effective dose is the dose or amount of an agent that produces a therapeutic response or desired effect in some fraction of the subjects taking it.
- the "median effective dose” or ED50 of an agent is the dose or amount of an agent that produces a therapeutic response or desired effect in 50% of the population to which it is administered.
- the ED50 is commonly used as a measure of reasonable expectance of an agent's effect, it is not necessarily the dose that a clinician might deem appropriate taking into consideration all relevant factors.
- the effective amount is more than the calculated ED50, in other situations the effective amount is less than the calculated ED50, and in still other situations the effective amount is the same as the calculated ED50.
- an effective dose of the IDO inhibitors of the present invention may be an amount that, when administered in one or more doses to a subject, produces a desired result relative to a healthy subject.
- an effective dose may be one that improves a diagnostic parameter, measure, marker and the like of that disorder by at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, where 100% is defined as the diagnostic parameter, measure, marker and the like exhibited by a normal subject.
- compositions can be provided in the form of tablets, capsules and the like containing from 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 3.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient.
- the dosage of the desired IDO inhibitor is contained in a "unit dosage form".
- unit dosage form refers to physically discrete units, each unit containing a predetermined amount of the IDO inhibitor, either alone or in combination with one or more additional agents, sufficient to produce the desired effect. It will be appreciated that the parameters of a unit dosage form will depend on the particular agent and the effect to be achieved. Kits
- kits comprising an IDO inhibitor, and pharmaceutical compositions thereof.
- the kits are generally in the form of a physical structure housing various components, as described below, and may be utilized, for example, in practicing the methods described above.
- a kit can include one or more of the IDO inhibitors disclosed herein (provided in, e.g., a sterile container), which may be in the form of a pharmaceutical composition suitable for administration to a subject.
- the IDO inhibitors can be provided in a form that is ready for use (e.g., a tablet or capsule) or in a form requiring, for example,
- the kit may also include diluents (e.g., sterile water), buffers, pharmaceutically acceptable excipients, and the like, packaged with or separately from the IDO inhibitors.
- diluents e.g., sterile water
- the kit may contain the several agents separately or they may already be combined in the kit.
- Each component of the kit may be enclosed within an individual container, and all of the various containers may be within a single package.
- a kit of the present invention may be designed for conditions necessary to properly maintain the components housed therein (e.g., refrigeration or freezing).
- kits may contain a label or packaging insert including identifying information for the components therein and instructions for their use (e.g., dosing parameters, clinical pharmacology of the active ingredient(s), including mechanism of action,
- Labels or inserts can include manufacturer information such as lot numbers and expiration dates.
- the label or packaging insert may be, e.g., integrated into the physical structure housing the components, contained separately within the physical structure, or affixed to a component of the kit (e.g., an ampule, tube or vial).
- Labels or inserts can additionally include, or be incorporated into, a computer readable medium, such as a disk (e.g., hard disk, card, memory disk), optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic/optical storage media, FLASH media or memory-type cards.
- a computer readable medium such as a disk (e.g., hard disk, card, memory disk), optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic/optical storage media, FLASH media or memory-type cards.
- the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g., via the internet, are provided.
- the sonicate can be centrifuged for 10 min at 10,000 x g, and the supernatant can be assayed in triplicate by incubating a 40 ⁇ l sample with an equal volume of 100 mmol/L potassium phosphate buffer, pH 6.5, containing 40 mmol/L ascorbic acid (neutralized to pH 7.0), 100 ⁇ mol/L methylene blue, 200 ⁇ g/mL catalase, and 400 ⁇ mol/l L-Trp for 30 min at 37 oC.
- the assay can be terminated by the addition of 16 ⁇ L 30% (w/v) trichloroacetic acid (TCA) and further incubated at 60 oC for 15 min to hydrolyze N-formylkynurenine to KYN.
- TCA trichloroacetic acid
- the mixture can then be centrifuged at 12,000 rpm for 15 min, and KYN can be quantified by mixing equal volume of supernatant with 2% (w/v) Ehrlich's reagent in glacial acetic acid in 96-well microtiter plate and reading the absorbance at 480 nm using L-KYN as standard.
- Protein in the islet samples can be quantified by Bio-Rad Protein assay at 595 nm.
- proteins can be precipitated with 5% (w/v) TCA and centrifuged at 12,000 rpm for 15 min, and determination of KYN in the supernatant with Ehrlich's reagent can be determined as described above.
- IL-4 (10 ⁇ g/mL; 500-2,000 units/mL) and 1- ⁇ -methyl Trp (1-MT; 40 ⁇ mol/L) can be added to the incubation media as indicated.
- This assay can also form the basis of a cell-based assay, and may be quantified via LCMS/MS as an alternative to UV/Vis detection.
- COS7 cells (0.6 ⁇ 10 6 cells/60 mm3 petri dish) transfected with human-IDO plasmid (3 ⁇ g) or empty vector cells can be used as positive and negative controls, respectively.
- Proteins can be transferred electrophoretically onto polyvinylidine fluoride membranes by semidry method and blocked for 1 h with 5% (w/v) nonfat dry milk in Tris-buffered saline and 0.1% Tween and then incubated overnight with anti-human mouse IDO antibody (1:500; Chemicon, Temecula, CA), phospho-STAT 1 ⁇ p91, and STAT 1 ⁇ p91 (1:500; Zymed, San Francisco, CA).
- Immunoreactive proteins can be visualized with ECL PLUS® Western blotting detection reagent (Amersham BioSciences,
- Immunofluorescent staining on islet tissue can be performed on 7 ⁇ m sections that were stained with antibodies raised against pancreatic duodenal homeobox 1 (PDX1) and IDO.
- Antigen retrieval can be performed in a water bath for 30 min in a buffer containing 10 mmol/l Tris and 1 mmol/l EDTA (pH 9.0) at 97 oC.
- the sections can be blocked for 1 h with 5% normal goat serum in PBS.
- the tissues can then be reacted with mouse monoclonal anti-human IDO antibody (1:20; Chemicon) and goat polyclonal anti-human PDX1 antibody (1:2,000; which may be requested from Dr. Chris Wright, School of Medicine, Vanderbilt, TN) overnight at room temperature in a humid chamber.
- Secondary antibodies anti-goat (labeled with Cy3) and anti-mouse (labeled with Cy2) can be purchased from Jackson Immunolabs and can be used at a concentration of 1:200.
- the nuclei can be stained with Hoechst 33258 (Molecular Probes, Eugene, OR). Images can be acquired by Intelligent Imaging System software from an Olympus 1X81 inverted motorized microscope equipped with Olympus DSU (spinning disk confocal) and
- Biochemical Assay cDNA clones for both human and mouse IDO have been isolated and verified by sequencing and are commercially available.
- C-terminal His-tagged IDO protein can be produced in E. coli using the IPTG-inducible pET5a vector system and isolated over a nickel column. The yield of the partially purified protein can be verified by gel electrophoresis and the concentration estimated by comparison to protein standards.
- a 96-well plate spectrophotometric assay for kynurenine production can be run following published procedures (see, e.g., Littlejohn, T.K. et al., Prot. Exp.
- compounds can be evaluated at a single concentration of, for example, 200 ⁇ M against 50 ng of IDO enzyme in 100 ⁇ L reaction volumes with tryptophan added at increasing concentrations at, for example, 0, 2, 20, and 200 ⁇ M. Kynurenine production can be measured at 1 hour.
- COS-1 cells can be transiently transfected with a CMV promoter-driven plasmid expressing IDO cDNA using Lipofectamine 2000 (Invitrogen) as recommended by the manufacturer.
- a companion set of cells can be transiently transfected with TDO-expressing plasmid.
- the cells can be apportioned into a 96-well format at 6 ⁇ 10 4 cells per well. The following day, the wells can be washed and new media (phenol red free) containing 20 ⁇ g/mL tryptophan can be added together with inhibitor.
- the reaction can be stopped at 5 hours and the supernatant removed and spectrophotometrically-assayed for kynurenine as previously described for the enzyme assay.
- compounds can be evaluated at a single concentration of, for example, 100 ⁇ M. More extensive dose-escalation profiles can be collected for select compounds.
- a pharmacodynamic assay can be based on measuring serum levels of both kynurenine and tryptophan, and calculating the kynurenine/tryptophan ratio provides an estimate of IDO activity that is independent of baseline tryptophan levels.
- Serum tryptophan and kynurenine levels can be determined by HPLC analysis, and serum compound levels can optionally also be determined in the same HPLC run.
- Compounds can be initially evaluated by challenging mice with LPS and then subsequently administering a bolus dose of compound at the time that the serum kynurenine level plateaus. As the kynurenine pool is rapidly turned over with a half-life in serum of less than 10 minutes, pre-existing kynurenine is not expected to unduly mask the impact that an IDO inhibitor has on kynurenine production.
- Each experiment can include non-LPS-exposed mice (to determine baseline kynurenine levels against which to compare the other mice) and a set of LPS-exposed mice dosed with vehicle alone (to provide a positive control for IDO activation). Each compound can initially be evaluated in mice at a single high i.p.
- bolus dose in the range of at least 100 mg/kg.
- Blood can be collected at defined time intervals (for example, 50 ⁇ L sample at 5, 15, 30 min., 1, 2, 4, 6, 8, and 24 hr. following compound administration) for HPLC analysis of kynurenine and tryptophan levels (pharmacodynamic analysis) as well as for the level of compound (pharmacokinetic analysis). From the pharmacokinetic data the peak serum concentration of compound achieved can be determined as well as the estimated rate of clearance. By comparing the level of compound in serum relative to the kynurenine/tryptophan ratio at various time points, the effective IC 50 for IDO inhibition in vivo can be roughly estimated. Compounds exhibiting efficacy can be evaluated to determine a maximum dose that achieves 100% IDO inhibition at the peak concentration.
- Method A Waters Acquity SDS using the following method: Linear Gradient of 2% to98% Solvent B over 1.7 min; UV visualization at 220 nm; Column: BEH C182.1 mm ⁇ 50 mm; 1.7 ⁇ m particle (Heated to Temp.50 oC); Flow rate: 0.8 ml/min; Mobile Phase A: 100% Water, 0.05% TFA; Mobile Phase B: 100% Acetonitrile, 0.05% TFA.
- Method B Column: Waters Acquity UPLC BEH C18, 2.1 ⁇ 50 mm, 1.7- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate;
- Mobile Phase B 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50 oC; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.00 mL/min; Detection: UV at 220 nm.
- Method C Waters SFC-100 MS, Column: Chiral OJ-H 25 ⁇ 3 cm ID, 5 ⁇ m Flow rate: 100.0 mL/min, Mobile Phase:80/20 CO 2 /MeOH, Detector Wavelength: 220 nm.
- Method D Aurora analytical SFC, Column: Chiral OJ-H 250 ⁇ 4.6 mm ID, 5 ⁇ m, Flow rate: 2.0 mL/min, Mobile Phase: 80/20 CO 2 /MeOH.
- Method E Berger Prep SFC, Column: Chiral AS 25 ⁇ 3 cm ID, 5 ⁇ m Flow rate: 85.0 mL/min, Mobile Phase:82/18 CO 2 /MeOH w/ 0.1% DEA, Detector Wavelength: 220 nm.
- Method F Aurora analytical SFC, Column: Chiral AS 250 ⁇ 4.6 mm ID, 5 ⁇ m, Flow rate: 2.0 mL/min, Mobile Phase: 80/20 CO 2 /MeOH w/ 0.1% DEA.
- Method G Berger Prep SFC, Column: Chiral AS 25 ⁇ 3 cm ID, 5 ⁇ m Flow rate: 85.0 mL/min, Mobile Phase:86/14 CO 2 /MeOH, Detector Wavelength: 220 nm.
- Method H Aurora analytical SFC, Column: Chiral AS 250 ⁇ 4.6 mm ID, 5 ⁇ m, Flow rate: 2.0 mL/min, Mobile Phase: 85/15 CO 2 /MeOH.
- Method I Column: Waters Acquity UPLC BEH C18, 2.1 ⁇ 50 mm, 1.7- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50 oC; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
- Method J Preparative Chromatographic Conditions: Instrument: Berger Prep SFC MGII (LVL-L4021 Lab) Column: Chiral IC 25 ⁇ 3 cm ID, 5 ⁇ m; Flow rate: 85.0 mL/min; Mobile Phase: 74/26 CO 2 /MeOH; Detector Wavelength: 220 nm.
- Method K Preparative Chromatographic Conditions: Instrument: Berger Prep SFC MGII (LVL-L4021 Lab) Column: Chiral IC 25 ⁇ 3 cm ID, 5 ⁇ m; Flow rate: 85.0 mL/min; Mobile Phase: 75/25 CO 2 /MeOH hold for 18 minutes, 60/40 CO 2 /MeOH hold for 11 minutes, 75/25 CO 2 /MeOH hold for 3 minutes; Detector Wavelength: 220 nm.
- Method L Preparative Conditions: Berger SFC MGII; Stage-1: Column: Chiral OD-H 25 ⁇ 3 cm ID, 5- ⁇ m particles; Mobile Phase:82/18 CO 2 /MeOH; Detector
- Analytical Conditions Aurora analytical SFC; Stage-1: Column: Chiral OD-H 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Flow: 2.0 mL/min; Stage-2: Column: Chiral IF 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Flow: 2.0 mL/min. Tr corresponds to the analytical condition.
- Method M Preparative Conditions: Berger SFC MGII; Stage-1: Column: Chiral OD-H 25 ⁇ 3 cm ID, 5- ⁇ m particles; Mobile Phase:80/20 CO 2 /MeOH; Detector
- Analytical Conditions Aurora analytical SFC; Stage-1: Column: Chiral OD-H 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Flow: 2.0 mL/min; Stage-2: Column: Chiral IF 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Flow: 2.0 mL/min. Tr corresponds to the analytical condition.
- Method N Preparative Conditions: Berger SFC MGII; Column: WHELK-O® 1 KROMASIL® 25 ⁇ 3 cm ID, 5- ⁇ m particles; Mobile Phase:80/20 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: WHELK-O® 1 KROMASIL® 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method O Preparative Conditions: Berger SFC MGII; Column: Chiral OJ 25 ⁇ 3 cm ID, 5- ⁇ m; Mobile Phase:90/10 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral AD 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method R Preparative Conditions: Berger SFC MGII; Column: Chiral AD 25 ⁇ 3 cm ID, 5- ⁇ m; Mobile Phase:87/13 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral AD 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:85/15 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method S Preparative Conditions: Berger SFC MGII; Column: Chiral IF 25 ⁇ 3 cm ID, 5- ⁇ m; Mobile Phase:75/25 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral IF 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:70/30 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method T Preparative Conditions: Waters SFC100-MS; Column: Chiral IC 25 ⁇ 3 cm ID, 5- ⁇ m coupled to WHELK-O® R,R KROMASIL® 25x3 cm ID 5- ⁇ m; Mobile Phase:70/30 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 100 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral IC 250 ⁇ 4.6 mm ID, 5 ⁇ m coupled to WHELK-O® R,R KROMASIL® 25x3 cm ID 5- ⁇ m; Mobile Phase:70/30 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method U Preparative Conditions: Waters SFC100-MS; Column: Chiral OJ-H 25 ⁇ 3 cm ID, 5- ⁇ m; Mobile Phase:70/30 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 100 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral OJ-H 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:70/30 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method V Preparative Conditions: Berger SFC MGII; Column: Chiral WHELK-O® 25 ⁇ 3 cm ID, 5- ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral WHELK-O® 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:80/20 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method W Preparative Conditions: Berger SFC MGII; Column: Chiral IC 25 ⁇ 3 cm ID, 5- ⁇ m; Mobile Phase:85/15 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral IC 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:85/15 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method X Preparative Conditions: Berger SFC MGII; Column: Chiral IC 25 ⁇ 3 cm ID, 5- ⁇ m; Mobile Phase:75/25 CO 2 /MeOH w/0.1% diethylamine; Detector
- Wavelength 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral IC 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase:75/25 CO 2 /MeOH w/0.1% diethylamine; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method Y Mobile Phase: 80/20 CO 2 /MeOH/CAN 50/50; Flow: 2.0 mL/min; Tr corresponds: Preparative Conditions: Berger SFC MGII; Column: Chiral AD 25 ⁇ 3 cm, 5- ⁇ m; Mobile Phase:80/20 CO 2 /MeOH/CAN 50/50; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral AD 250 ⁇ 4.6 mm ID, 5 ⁇ m; to the analytical condition.
- Method Z Preparative Conditions: Berger SFC MGII; Column: Chiral IC 25 ⁇ 3 cm, 5- ⁇ m; Mobile Phase:83/17 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral IC 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase: 80/20 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method AA Preparative Conditions: Waters SFC100-MS; Column: Chiral AS- H coupled Chiral OJ-H 25 ⁇ 3 cm, 5- ⁇ m; Mobile Phase:70/30 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 100 mL/min.
- Analytical Conditions AGILENT® analytical SFC; Column: Chiral AS-H coupled to Chiral OJ-H 250 ⁇ 4.6 mm ID, 5 ⁇ m; Mobile Phase: 70/30 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method AB Waters Acquity SDS using the following method: Linear Gradient of 2% to98% Solvent B over 1.6 min; UV visualization at 220 nm; Column: BEH C182.1 mm ⁇ 50 mm; 1.7 ⁇ m particle (Heated to Temp.50 oC); Flow rate: 1 ml/min; Mobile Phase A: 100% Water, 0.05% TFA; Mobile Phase B: 100% Acetonitrile, 0.05% TFA.
- Method AC Preparative Conditions: Berger SFC MGII; Column: Chiral AD 25 X 3 cm ID, 5- ⁇ m; Mobile Phase:90/10 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Chiral AD 250 X 4.6 mm ID, 5 ⁇ m; Mobile Phase:90/20 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method AD Preparative Conditions: Berger SFC MGII; Column: Whelk-O1 Kromasil 25 X 3 cm ID, 5- ⁇ m particles; Mobile Phase:85/15 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Whelk-O1 Kromasil 250 X 4.6 mm ID, 5 ⁇ m; Mobile Phase:85/15 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Method AE Preparative Conditions: Berger SFC MGII; Column: Whelk-O1 Kromasil 25 X 3 cm ID, 5- ⁇ m particles; Mobile Phase:75/25 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Analytical Conditions Aurora analytical SFC; Column: Whelk-O1 Kromasil 250 X 4.6 mm ID, 5 ⁇ m; Mobile Phase:75/25 CO 2 /MeOH; Flow: 2.0 mL/min; Tr corresponds to the analytical condition.
- Cis-4-phenylcyclohexane-1-carbaldehyde Prepared according the literature procedure (Fox, B.M. et al., J. Med. Chem., 57:3464-3483 (2014)). The crude mixture was purified using silica gel chromatography (0% to 10% EtOAc in hexane) to afford the desired product as the first eluting isomer.
- Cis-(4-phenylcyclohexyl)methanol To a solution of cis-4-phenylcyclohexane- 1-carbaldehyde (825 mg, 4.4 mmol) in THF (25 mL) and MeOH (7 mL) at rt was added NaBH 4 portionwise over 5 min. The resulting mixture was stirred at rt for 45 min. Then HCl (1 M) was added dropwise. The mixture was extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over Na 2 SO 4 and concentrated under reduced pressure. The resulting crude mixture was purified employing silica gel chromatography (0% to 25% EtOAc in hexanes) to afford the desired product.
- Cis-(4-(iodomethyl)cyclohexyl)benzene To a solution of cis-(4- phenylcyclohexyl)methanol (2 g, 10.5 mmol), triphenylphosphine (3.3 g, 12.6 mmol) and imidazole (1.1 g, 15.8 mmol) in CH 2 Cl 2 (70 mL) at 0 oC was added iodine (3.5 g, 13.7 mmol). The mixture was warmed to rt and stirred at rt for 2 h. The mixture was diluted with CH 2 Cl 2 and washed with sodium thiosulfate (2 M).
- Cis-(4-(azidomethyl)cyclohexyl)benzene To a solution of cis-(4- (iodomethyl)cyclohexyl)benzene (2.6 g, 8.8 mmol) in DMF (44 mL) was added sodium azide (2.8 g, 43.8 mmol). The mixture was stirred at rt for 2 h. Then more sodium azide (1.14 g, 17.5 mmol) was added and the mixture was stirred at rt for 18 h. The mixture was diluted with Et 2 O and washed with water, 1 M LiCl (2x) and brine. The organic layers were dried over Na 2 SO 4 and concentrated under reduced pressure to give the desired product (1.5 g, 80%).
- Cis-(4-phenylcyclohexyl)methanamine To a solution of cis-(4-(azidomethyl) cyclohexyl)benzene (1.5 g, 7.0 mmol) in THF (35 mL) was added triphenylphosphine (2.56 g, 9.8 mmol). The mixture was stirred at rt for 30 min and then water (0.83 mL) was added. The mixture was stirred at rt for 24 h. The mixture was preabsorbed onto silica gel and purified employing silica gel chromatography [0% to 5% (2 M NH 3 in MeOH) in CH 2 Cl 2 ] to afford the desired product as an oil (1.2 g, 94%).
- the mixture was stirred at rt for 2 hours.
- the mixture of the cyclohexanone was added to the phosphonate mixture at 0 oC via cannulation.
- the mixture was warmed to rt and stirred at rt for 2 h.
- the mixture was quenched by careful addition of ice and water (1 L) and subsequently extracted with ethyl acetate (3x 500 mL) and the combined organics were then washed with brine (1L), dried over sodium sulfate, filtered, and concentrated to provide ethyl 2-(4-(4-hydroxyphenyl)cyclohexylidene)acetate in 97% yield as a white solid.
- Example 9E cis-N-(4-chlorophenyl)-2-(4-(4- methoxyphenyl)cyclohexyl)acetamide
- Example 9F trans-N-(4-chlorophenyl)-2-(4-(4-methoxyphenyl)cyclohexyl)acetamide
- 3-Phenylcyclopentan-1-one was prepared as previously described (Yamamoto, T. et al., J. Organomet. Chem., 694:1325-1332 (2009)). To a solution of 3- phenylcyclopentan-1-one (1.0 g, 6.2 mmol) in 30 mL of methanol cooled to 0 oC was added NaBH 4 (0.27 g, 7.2 mmol). The ice bath was removed, and the reaction was allowed to warm to rt and stirred for 3 h. The reaction was quenched with 1 M HCl and diluted with EtOAc (30 mL), and the layers were separated.
- reaction solution was diluted with EtOAc (60 mL), washed with 1 N NaOH (50 mL), dried over anhydrous MgSO 4 , filtered, and concentrated under reduced pressure.
- the crude residue was purified using silica gel chromatography (0% to 100% EtOAc in hexanes) to afford the desired product as a white solid. m/z 254.2 (M+H + ).
- the mixture was allowed to warm to rt and stirred for 16 h.
- the reaction mixture was diluted with EtOAc (50 mL), filtered through a pad of 1:1 CELITE®:silica gel, and concentrated under reduced pressure.
- the crude residue was purified using silica gel chromatography (0% to 18%, then 18% to 30% EtOAc in hexanes) to afford the desired product as a white solid.
- Example 34 4-Fluoro-N-(1,1,1-trifluoro-3-(4-(4-methoxyphenyl)cyclohexyl)propan-2- yl)aniline
- the flask was evacuated and backfilled with N 2 three times, before degassed dioxane (100 mL) and water (10 mL) were added to the solids and the mixture was stirred and heated to 90 oC under N 2 atmosphere. After 16 h, the mixture was cooled to rt, and SiO 2 was added. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (0% to 100% EtOAc in hexanes) to give 4- (1,4-dioxaspiro[4.5]dec-7-en-8-yl)quinoline (3.2g, 50%).
- Preparation 40D (100 g, 0.348 mol) was treated with 4 N HCl ( 300 mL) in acetone (1200 mL) at 45°C overnight. The mixture was monitored by TLC. Then the solution was concentrated in vacuo. The residue was adjusted to pH 9 with 6 N NaOH. and the mixture was partitioned between ethyl acetate and water.
- the reaction was poured slowly onto 500 mL of saturated aqueous ammonium chloride and 500 g of ice.
- the resulting aqueous solution was extracted with EtOAc (3 x 300 mL) and the combined organic fractions were washed with saturated aqueous ammonium chloride (250 mL) and saturated aqueous sodium chloride (250 mL).
- the organic portion was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- Sufficient silica to adsorb the oil was added and diluted with 10 % MeOH in CH2Cl2. A similar quantity of silica was used as a silica plug to purify the material.
- the heterogeneous mixture was quenched by the addition of saturated aqueous ammonium chloride (200 mL) and extracted with CH2Cl2 (3 x 300 mL). The combined organic fractions were dried over anhydrous sodium sulfate and concentrated under reduced pressure. Excess pyridine was removed by azeotroping from toluene (3 x 300 mL). The crude material was recrystallized from H2O/MeOH as follows: 1 mL/mmol of H2O was added and the slurry was heated to 120 °C in an oil bath. MeOH was added until the solids went into solution ( ⁇ 0.5 L).
- the reaction mixture was rapidly diluted with saturated aqueous ammonium chloride solution (400 mL) and the biphasic mixture was stirred for 15 min.
- i PrOAc 100 mL was added, the layers were separated, and the aqueous layer was extracted with i PrOAc (3 x 50 mL).
- the combined organic extracts were dried over anhydrous magnesium sulfate filtered, and concentrated.
- the resulting residue was recrystallized by dissolving in 400 mL hot acetone and adding H 2 O until a milky solution formed followed to re-dissolving with heating ( ⁇ 3:1 acetone/H 2 O).
- Preparation 40J was obtained as white needles (15.04 g, 2 crops, 68 %).
- Examples 41 to 46 were prepared from Preparation 40L following the procedure for Example 40 using the corresponding sulfonyl chlorides.
- Examples 48 to 69 were prepared from Preparation 40L following the procedure for Example 47 using the corresponding benzoic acids.
- Example 70 N-((R)-1-((cis)-4-(6-fluoroquinolin-4-yl)cyclohexyl) ethyl)-[1,1 ⁇ -biphenyl]- 4-carboxamide
- Triethyl phosphonoacetate (21.79 ml, 109 mmol) was added to a suspension of sodium hydride (3.84 g, 96 mmol) in THF (64.0 ml) and 0 oC. Reaction was stirred at room temperature for 30 minutes. After 30 minutes, the reaction was recooled to 0 oC and a solution of 1,4-dioxaspiro[4.5]decan-8-one (10 g, 64.0 mmol) in 5 mL THF was added. The reaction was then stirred at room temperature for 30 minutes prior to quenching with water. The mixture was extracted with DCM three times.
- T r 2.126 min (Method A).
- Example 72 was prepared from Intermediate 71E and the analogous procedures outlined to make 71F, 71G, 71H, and Example 71 except that 4-chloro-8- (trifluoromethyl) quinoline was used in part F.
- Example 78
- Example 78 was synthesized from Intermediate 71E following the same procedures used to make Intermediates 77A, 77B, 77C and Example 77a using 4- hydroxy-6-trifluoromethyl quinoline rather than pyridin-4-ol in the synthesis of 77A.
- LC- MS Anal. Calc'd for C 26 H 26 ClF 3 N 2 O 2 490.16, found [M+H] 491.2 T r 0.86 min (Method A).
- Example 79a was synthesized from Intermediate 71E following the same procedures used to make Intermediates 77A, 77B, 77C and Example 77a using 4- hydroxy-2-trifluoromethyl quinoline rather than pyridin-4-ol in the synthesis of 77A.
- LC- MS Anal. Calc'd for C 26 H 26 ClF 3 N 2 O 2 490.16, found [M+H] 491.2 T r 1.13 min (Method A).
- Example 80 was synthesized from Intermediate 71E following the same procedures used to make Intermediates 77A, 77B, 77C and Example 77 using 4- hydroxyquinoline rather than pyridin-4-ol as in the synthesis of 77A.
- LC-MS Anal. Calc'd for C 25 H 27 ClN 2 O 2 422.18, found [M+H] 423.2 T r 0.78 min (Method A).
- Example 92 (19.3 mg; 49% yield) was prepared following a procedure analogous to that for the synthesis of Example 91, except that 4-chloro-2-fluoro-1- isocyanatobenzene (19.4 mg, 0.11 mmol) was used instead of 1-isocyanato-4- methylbenzene.
- MS(ES): m/z 417 [M+H] + .
- T r 1.42 min (Method I).
- Example 93 (21.8 mg; 61% yield) was prepared following a procedure analogous to that for the synthesis of Example 91, except that 1-fluoro-4- isocyanatobenzene (15.5 mg, 0.11 mmol) was used instead of 1-isocyanato-4- methylbenzene.
- MS(ES): m/z 383 [M+H] + .
- T r 1.18 min (Method I).
- the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 ⁇ 200 mm, 5- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 30- 70% B over 22 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation.
- the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 ⁇ 200 mm, 5- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 30- 70% B over 22 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation.
- Example 131 was obtained following the procedures in Example 130 using the corresponding cis-4-(6-fluoroquinolin-4-yl)cyclohexanone and benzylamine.
- the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 ⁇ 200 mm, 5- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 50- 100% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation.
- the reaction mixture was filtered and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 ⁇ 200 mm, 5- ⁇ m particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: 25-100% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min.
- the material was further purified through chiral separation. An approximately 140 mg sample was resolved.
- the material was purified via preparative SFC with the following conditions: Column: Chiral AD 25 ⁇ 3 cm ID, 5- ⁇ m particles; Mobile Phase : 70/30 CO 2 /MeOH; Detector Wavelength: 220 nm; Flow: 85 mL/min.
- Ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate (13.88 g, 61.3 mmol) was taken up in EtOAc (61.3 ml) and was added to a Parr hydrogenation bottle containing 10 % palladium on carbon (1.306 g, 12.27 mmol) (54% w/w water) under an atmosphere of nitrogen. The reaction bottle was purged with nitrogen, then with hydrogen. After filling the bottle with hydrogen to 50 psi, the bottle was placed in a Parr shaker and shaken.
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580060328.5A CN106999450B (en) | 2014-11-05 | 2015-11-05 | Immunomodulator |
CA2964297A CA2964297A1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
AU2015342944A AU2015342944A1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
SG11201702827VA SG11201702827VA (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
KR1020177015284A KR102647639B1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
ES15857810T ES2867748T3 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
EP15857810.4A EP3215142B1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
JP2017524423A JP6762299B2 (en) | 2014-11-05 | 2015-11-05 | Immunomodulator |
BR112017007782A BR112017007782A2 (en) | 2014-11-05 | 2015-11-05 | immunoregulatory agents |
US15/524,092 US20180325889A1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
MX2017005729A MX2017005729A (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents. |
MA40290A MA40290A1 (en) | 2014-11-05 | 2015-11-05 | Immune-regulating agents |
TN2017000165A TN2017000165A1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
EA201790998A EA201790998A1 (en) | 2014-11-05 | 2015-11-05 | IMMUNOREGULATING AGENTS |
MA44549A MA44549A1 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
PH12017500604A PH12017500604A1 (en) | 2014-11-05 | 2017-04-03 | Immunoregulatory agents |
IL252010A IL252010A0 (en) | 2014-11-05 | 2017-04-28 | Immunoregulatory agents |
CONC2017/0005218A CO2017005218A2 (en) | 2014-11-05 | 2017-05-25 | Compounds that modulate the enzyme indolamine 2,3-dioxygenase (ido) oxidoreductase and compositions comprising the compounds " |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075678P | 2014-11-05 | 2014-11-05 | |
US62/075,678 | 2014-11-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016073774A2 true WO2016073774A2 (en) | 2016-05-12 |
WO2016073774A3 WO2016073774A3 (en) | 2016-07-07 |
Family
ID=55910037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/059316 WO2016073774A2 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
Country Status (23)
Country | Link |
---|---|
US (3) | US20180325889A1 (en) |
EP (1) | EP3215142B1 (en) |
JP (1) | JP6762299B2 (en) |
KR (1) | KR102647639B1 (en) |
CN (1) | CN106999450B (en) |
AR (1) | AR102537A1 (en) |
AU (1) | AU2015342944A1 (en) |
BR (1) | BR112017007782A2 (en) |
CA (1) | CA2964297A1 (en) |
CL (1) | CL2017001126A1 (en) |
CO (1) | CO2017005218A2 (en) |
EA (1) | EA201790998A1 (en) |
ES (1) | ES2867748T3 (en) |
IL (1) | IL252010A0 (en) |
MA (2) | MA44549A1 (en) |
MX (1) | MX2017005729A (en) |
PE (1) | PE20171623A1 (en) |
PH (1) | PH12017500604A1 (en) |
SG (1) | SG11201702827VA (en) |
TN (1) | TN2017000165A1 (en) |
TW (1) | TW201630866A (en) |
UY (1) | UY36391A (en) |
WO (1) | WO2016073774A2 (en) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9598422B2 (en) | 2014-11-05 | 2017-03-21 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9643972B2 (en) | 2014-11-05 | 2017-05-09 | Flexus Biosciences, Inc. | Immunoregulatory agents |
WO2018024188A1 (en) * | 2016-08-02 | 2018-02-08 | 上海迪诺医药科技有限公司 | Polycyclic compound, and manufacturing method, pharmaceutical composition, and application thereof |
CN107674029A (en) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | Polycyclic compound, its pharmaceutical composition and application |
WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019006292A1 (en) | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation |
WO2019057123A1 (en) | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
CN109641881A (en) * | 2016-06-10 | 2019-04-16 | 伊莱利利公司 | 1- THP trtrahydropyranyl carbonyl -2,3- dihydro -1H- benzazolyl compounds for treating cancer |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN109843322A (en) * | 2016-08-26 | 2019-06-04 | 百时美施贵宝公司 | The inhibitor and its application method of indole amine 2,3-dioxygenase |
WO2019111107A1 (en) * | 2017-12-05 | 2019-06-13 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019170543A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
KR20200020916A (en) * | 2017-06-30 | 2020-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Amorphous and Crystalline Forms of IDO Inhibitors |
JP2020506895A (en) * | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and / or tryptophan dioxygenase |
CN110878013A (en) * | 2019-12-13 | 2020-03-13 | 西安瑞联新材料股份有限公司 | Synthesis method of (trans ) -4-vinyl-4' - [ (E) -1-propenyl ] -bicyclohexane |
US10633342B2 (en) | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10800757B2 (en) | 2017-10-27 | 2020-10-13 | Boehringer Ingelheim International Gmbh | Inhibitors of TRPC6 |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US11046682B2 (en) | 2016-08-23 | 2021-06-29 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3747865A4 (en) * | 2018-01-29 | 2021-10-20 | Beijing InnoCare Pharma Tech Co., Ltd. | Pentafluorosulfanyl-substituted amide compound, preparation method therefor, and medical application thereof |
JP2021529806A (en) * | 2018-07-06 | 2021-11-04 | ギリアード サイエンシーズ, インコーポレイテッド | Therapeutic heterocyclic compounds |
US11180497B2 (en) | 2017-10-18 | 2021-11-23 | Angex Pharmaceutical, Inc. | Cyclic compounds as immunomodulating agents |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
WO2022184930A2 (en) | 2021-03-05 | 2022-09-09 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
MX2018002586A (en) | 2015-09-01 | 2020-11-24 | First Wave Bio Inc | Methods and compositions for treating conditions associated with an abnormal inflammatory responses. |
CA3037253A1 (en) * | 2016-09-26 | 2018-03-29 | Advantagene, Inc. | Methods of treating tim-3 elevation |
AU2017382405B2 (en) | 2016-12-22 | 2021-12-16 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
CN111386117A (en) * | 2017-09-29 | 2020-07-07 | 百时美施贵宝公司 | Compositions and methods for treating cancer |
WO2019074747A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | Novel substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
WO2019074749A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | Novel substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
CN109928921A (en) * | 2017-12-18 | 2019-06-25 | 成都华健未来科技有限公司 | IDO inhibitor |
CN109956929B (en) * | 2017-12-22 | 2023-09-19 | 上海迪诺医药科技有限公司 | Heterocyclic derivative, preparation method, pharmaceutical composition and application thereof |
WO2019120256A1 (en) * | 2017-12-22 | 2019-06-27 | 上海迪诺医药科技有限公司 | Five-membered heteroaryl ring derivative, pharmaceutical composition containing same, and application thereof |
CN109956937A (en) * | 2017-12-22 | 2019-07-02 | 上海海雁医药科技有限公司 | N- (2- cyclohexyl-ethyl) carboxamides derivatives, its preparation method and purposes pharmaceutically |
CN109574988B (en) * | 2017-12-25 | 2022-01-25 | 成都海博锐药业有限公司 | Compound and application thereof |
AU2019205904A1 (en) | 2018-01-05 | 2020-06-18 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
WO2019139902A1 (en) * | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Benzamide compounds |
WO2019141095A1 (en) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | Amidine and guanidine derivative, preparation method therefor and medical use thereof |
CN110066271B (en) * | 2018-01-23 | 2023-04-07 | 上海迪诺医药科技有限公司 | Pyrrole derivative, preparation method thereof, pharmaceutical composition and application thereof |
CN110066236B (en) * | 2018-01-24 | 2023-03-24 | 上海迪诺医药科技有限公司 | 1H-pyrrole derivative, preparation method thereof, pharmaceutical composition and application thereof |
CN111868032B (en) * | 2018-02-11 | 2021-09-03 | 基石药业(苏州)有限公司 | Kynurenine pathway inhibitors |
CN110156656B (en) * | 2018-02-13 | 2023-04-07 | 上海迪诺医药科技有限公司 | Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application |
JP7386797B2 (en) * | 2018-02-28 | 2023-11-27 | ダート・ニューロサイエンス・エルエルシー | Substituted cyclohexyl compounds as NOP inhibitors |
WO2019179369A1 (en) * | 2018-03-19 | 2019-09-26 | 四川科伦博泰生物医药股份有限公司 | Ring-containing compound, preparation method therefor, and medical application thereof |
CN110357813A (en) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application |
CN110498769A (en) * | 2018-05-17 | 2019-11-26 | 南京药捷安康生物科技有限公司 | IDO inhibitor and application |
CN110105275B (en) * | 2018-05-28 | 2020-12-29 | 上海海雁医药科技有限公司 | Amide derivatives, preparation method and medical application thereof |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
WO2021230710A1 (en) * | 2020-05-15 | 2021-11-18 | (주)신테카바이오 | Novel ido/tdo inhibitor, anticancer use thereof, and anticancer combination therapy thereof |
KR102653960B1 (en) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | Immune checkpoint inhibitor combination therapy for treating cancer |
KR20240019340A (en) * | 2021-06-11 | 2024-02-14 | 뉴로내슨트, 아이엔씨. | Methods and compositions for lipid preparations of lipophilic small molecule therapy of heterocyclic type |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029310A2 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan and its analogs |
WO2001092204A1 (en) | 2000-06-01 | 2001-12-06 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
WO2004094409A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
WO2005080317A2 (en) | 2004-02-11 | 2005-09-01 | Pfizer Japan, Inc. | Therapeutic amide derivatives |
WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3169188B2 (en) * | 1991-01-31 | 2001-05-21 | 杏林製薬株式会社 | Carbamic acid derivative and method for producing the same |
AU666040B2 (en) | 1992-10-28 | 1996-01-25 | Bayer Aktiengesellschaft | Substituted 1-H-3-aryl-pyrrolidine-2,4-dione derivatives |
DE4239151A1 (en) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | N, N-disubstituted arylcycloalkylamines, their salts, medicaments containing them and their use, and processes for their preparation |
GB9411099D0 (en) | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
CO5150225A1 (en) | 1999-03-19 | 2002-04-29 | Merck Sharp & Dohme | DERIVATIVES OF TETRAHYDROPIRANE AND ITS USE AS THERAPEUTIC AGENTS |
WO2000071171A2 (en) * | 1999-05-21 | 2000-11-30 | Wake Forest University | Sigma-1 ligands for determining carcinoma proliferative status |
US6291499B1 (en) * | 1999-10-29 | 2001-09-18 | Merck & Co., Inc. | 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
US20020002171A1 (en) * | 2000-01-28 | 2002-01-03 | Chalquest Richard R. | Materials and methods for killing nematodes and nematode eggs |
US6677336B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
EP1296953A2 (en) * | 2000-06-23 | 2003-04-02 | Eli Lilly And Company | Methods and compounds for inhibiting mrp1 |
ATE281431T1 (en) * | 2000-09-11 | 2004-11-15 | Pfizer Prod Inc | RESORCIN DERIVATIVES |
WO2002024613A2 (en) * | 2000-09-21 | 2002-03-28 | Pfizer Products, Inc. | Resorcinol derivatives |
EP1217000A1 (en) * | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
PL212089B1 (en) * | 2002-03-13 | 2012-08-31 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase |
MY134200A (en) * | 2002-04-12 | 2007-11-30 | Kowa Co | Method for treating cancer |
US20040029887A1 (en) | 2002-05-23 | 2004-02-12 | Bhatia Pramila A. | Acetamides and benzamides that are useful in treating sexual dysfunction |
MXPA05005425A (en) * | 2002-11-22 | 2005-11-23 | Japan Tobacco Inc | Fused bicyclic nitrogen-containing heterocycles. |
CA2509711A1 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
GEP20084341B (en) * | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US7750160B2 (en) * | 2003-11-13 | 2010-07-06 | Ambit Biosciences Corporation | Isoxazolyl urea derivatives as kinase modulators |
DE102004023507A1 (en) * | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Substituted cyclohexylacetic acid derivatives |
DE102004039789A1 (en) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
TW200720231A (en) * | 2005-04-21 | 2007-06-01 | Dainippon Sumitomo Pharma Co | An n-substituted phenylacetamide derivative and a pharmaceutical composition thereof |
AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
US20070004763A1 (en) * | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
CN105330741B (en) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
JP5335432B2 (en) * | 2005-11-17 | 2013-11-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | Fused bicyclic mTOR inhibitor |
WO2007082079A2 (en) * | 2006-01-12 | 2007-07-19 | The Scripps Research Institute | Piperidine amide derivatives as protein kinase inhibitors |
JP5372737B2 (en) * | 2006-03-13 | 2013-12-18 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | Combination therapy using EGFR kinase inhibitors and agents that sensitize tumor cells to the effects of EGFR kinase inhibitors |
WO2007109288A2 (en) | 2006-03-20 | 2007-09-27 | Xytis Inc. | Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use |
WO2007137107A2 (en) * | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
RS52464B (en) | 2006-06-01 | 2013-02-28 | Sanofi | Spirocyclic nitriles as protease inhibitors |
US20080119491A1 (en) | 2006-09-19 | 2008-05-22 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CA2668579A1 (en) | 2006-11-06 | 2008-06-05 | Neurogen Corporation | Cis-cyclohexyl substituted pyrimidinone derivatives |
EP2129660A2 (en) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
AU2007343726A1 (en) * | 2006-12-26 | 2008-07-24 | Amgen Inc. | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases |
CN101611012B (en) * | 2006-12-27 | 2012-11-14 | 塞诺菲-安万特股份有限公司 | Cycloalkylamine substituted isoquinoline derivatives |
CA2685029A1 (en) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Multi-ring compounds and uses thereof |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP2170059B1 (en) * | 2007-06-20 | 2014-11-19 | Merck Sharp & Dohme Corp. | Cetp inhibitors derived from benzoxazole arylamides |
WO2009000085A1 (en) * | 2007-06-27 | 2008-12-31 | Painceptor Pharma Corporation | Quinoline and quinazoline derivatives useful as modulators of gated ion channels |
EP2178563A2 (en) * | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
ES2591281T3 (en) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Combination therapies that employ GITR binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CA2702946A1 (en) * | 2007-10-16 | 2009-04-23 | Northeastern University | Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity |
KR20230085944A (en) * | 2008-03-18 | 2023-06-14 | 아레나 파마슈티칼스, 인크. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
CN102046595B (en) | 2008-03-27 | 2014-03-05 | 格吕伦塔尔有限公司 | Substituted 4-aminocyclohexane derivatives |
US20110039860A1 (en) * | 2008-05-07 | 2011-02-17 | Cangming Yang | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
KR101783004B1 (en) | 2008-07-08 | 2017-09-28 | 인사이트 홀딩스 코포레이션 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
SI2376535T1 (en) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
RU2505540C2 (en) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Antiviral compounds |
WO2010094126A1 (en) * | 2009-02-23 | 2010-08-26 | Merck Frosst Canada Ltd. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
LT3023438T (en) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
ES2722300T3 (en) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Antibodies that preferentially bind to extracellular domain 4 of CSF1R and its use |
ME03447B (en) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
BR112012022046A2 (en) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | "antibody, pharmaceutical composition, nucleic acid, expression vectors, host cell and method for producing a recombinant antibody". |
CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
JP5266430B2 (en) | 2010-04-24 | 2013-08-21 | ヴィアメット ファーマスーティカルズ,インコーポレイテッド | Metalloenzyme inhibitory compounds |
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
KR101527300B1 (en) | 2010-09-09 | 2015-06-09 | 화이자 인코포레이티드 | 4-1bb binding molecules |
EP2655110B1 (en) | 2010-12-23 | 2017-11-15 | Magna Powertrain of America, Inc. | Controlled gerotor actuated pre-trans parallel hybrid |
LT2699264T (en) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2012158784A2 (en) * | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
CA2849109C (en) * | 2011-09-22 | 2020-07-21 | Merck Sharp & Dohme B.V. | N-piperidin-4-yl derivatives |
TW201326154A (en) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | Novel 2H-indazoles as EP2 receptor antagonists |
KR101981873B1 (en) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | Anti-pd-l1 antibodies and uses thereof |
WO2013086002A1 (en) * | 2011-12-05 | 2013-06-13 | Cellworks Research India Private Limited | Compositions, process of preparation of said compositions and method of treating cancer |
KR20140127855A (en) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Compositions and methods for using csf1r inhibitors |
AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
JO3342B1 (en) * | 2012-06-26 | 2019-03-13 | Bayer Pharma AG | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
WO2014007998A1 (en) * | 2012-07-06 | 2014-01-09 | The Regents Of The University Of California | SORAFENIB DERIVATIVES AS p21 INHIBITORS |
EP3981791A1 (en) | 2012-08-30 | 2022-04-13 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
LT2970155T (en) * | 2013-03-15 | 2018-06-25 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (ido) |
WO2014160967A2 (en) * | 2013-03-29 | 2014-10-02 | Biomed Valley Discoveries, Inc. | C. novyi for the treatment of solid tumors in non-human animals |
BR112016028255A2 (en) * | 2014-06-06 | 2017-08-22 | Flexus Biosciences Inc | immunoregulatory agents |
GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
AR102537A1 (en) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | IMMUNOMODULATING AGENTS |
CN107205970A (en) | 2014-11-05 | 2017-09-26 | 弗莱塞斯生物科学公司 | Immunomodulator |
UY36390A (en) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
-
2015
- 2015-11-04 AR ARP150103582A patent/AR102537A1/en unknown
- 2015-11-04 UY UY0001036391A patent/UY36391A/en unknown
- 2015-11-05 EP EP15857810.4A patent/EP3215142B1/en active Active
- 2015-11-05 CN CN201580060328.5A patent/CN106999450B/en active Active
- 2015-11-05 MA MA44549A patent/MA44549A1/en unknown
- 2015-11-05 KR KR1020177015284A patent/KR102647639B1/en active IP Right Grant
- 2015-11-05 AU AU2015342944A patent/AU2015342944A1/en not_active Abandoned
- 2015-11-05 EA EA201790998A patent/EA201790998A1/en unknown
- 2015-11-05 PE PE2017000811A patent/PE20171623A1/en not_active Application Discontinuation
- 2015-11-05 WO PCT/US2015/059316 patent/WO2016073774A2/en active Application Filing
- 2015-11-05 MA MA40290A patent/MA40290A1/en unknown
- 2015-11-05 US US15/524,092 patent/US20180325889A1/en not_active Abandoned
- 2015-11-05 CA CA2964297A patent/CA2964297A1/en not_active Abandoned
- 2015-11-05 TW TW104136570A patent/TW201630866A/en unknown
- 2015-11-05 JP JP2017524423A patent/JP6762299B2/en active Active
- 2015-11-05 SG SG11201702827VA patent/SG11201702827VA/en unknown
- 2015-11-05 ES ES15857810T patent/ES2867748T3/en active Active
- 2015-11-05 TN TN2017000165A patent/TN2017000165A1/en unknown
- 2015-11-05 MX MX2017005729A patent/MX2017005729A/en unknown
- 2015-11-05 US US14/933,879 patent/US9598422B2/en active Active
- 2015-11-05 BR BR112017007782A patent/BR112017007782A2/en not_active IP Right Cessation
-
2017
- 2017-02-01 US US15/422,118 patent/US10206893B2/en active Active
- 2017-04-03 PH PH12017500604A patent/PH12017500604A1/en unknown
- 2017-04-28 IL IL252010A patent/IL252010A0/en unknown
- 2017-05-05 CL CL2017001126A patent/CL2017001126A1/en unknown
- 2017-05-25 CO CONC2017/0005218A patent/CO2017005218A2/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029310A2 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan and its analogs |
WO2001092204A1 (en) | 2000-06-01 | 2001-12-06 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
WO2004094409A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
WO2005080317A2 (en) | 2004-02-11 | 2005-09-01 | Pfizer Japan, Inc. | Therapeutic amide derivatives |
WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
Non-Patent Citations (7)
Title |
---|
BALL, H.J. ET AL., GENE, vol. 396, no. 1, 1 July 2007 (2007-07-01), pages 203 - 213 |
BIOORG. MED. CHEM. LETT., vol. 24, 2014, pages 5377 |
BRANDACHER, G. ET AL., CLIN. CANCER RES., vol. 12, no. 4, 15 February 2006 (2006-02-15), pages 1144 - 1151 |
LI, G. ET AL., BIOORG. MED. CHEM. LETT., vol. 18, 2008, pages 1146 - 1150 |
See also references of EP3215142A4 |
SERAFINI, P. ET AL., SEMIN. CANCER BIOL., vol. 16, no. 1, February 2006 (2006-02-01), pages 53 - 65 |
YAMAMOTO, T. ET AL., J. ORGANOMET. CHEM., vol. 694, 2009, pages 1325 - 1332 |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10206893B2 (en) | 2014-11-05 | 2019-02-19 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10106546B2 (en) | 2014-11-05 | 2018-10-23 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10533014B2 (en) | 2014-11-05 | 2020-01-14 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11932601B2 (en) | 2014-11-05 | 2024-03-19 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9643972B2 (en) | 2014-11-05 | 2017-05-09 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9598422B2 (en) | 2014-11-05 | 2017-03-21 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10633342B2 (en) | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN109641881B (en) * | 2016-06-10 | 2022-01-07 | 伊莱利利公司 | 1-tetrahydropyranyl carbonyl-2, 3-dihydro-1H-indole compounds for use in the treatment of cancer |
CN109641881A (en) * | 2016-06-10 | 2019-04-16 | 伊莱利利公司 | 1- THP trtrahydropyranyl carbonyl -2,3- dihydro -1H- benzazolyl compounds for treating cancer |
CN107674029A (en) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | Polycyclic compound, its pharmaceutical composition and application |
CN107674013B (en) * | 2016-08-02 | 2022-05-24 | 上海迪诺医药科技有限公司 | Polycyclic compound, preparation method, pharmaceutical composition and application thereof |
WO2018024188A1 (en) * | 2016-08-02 | 2018-02-08 | 上海迪诺医药科技有限公司 | Polycyclic compound, and manufacturing method, pharmaceutical composition, and application thereof |
CN107674013A (en) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | Polycyclic compound, its preparation method, pharmaceutical composition and application |
US11046682B2 (en) | 2016-08-23 | 2021-06-29 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof |
US11351164B2 (en) | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN109843322A (en) * | 2016-08-26 | 2019-06-04 | 百时美施贵宝公司 | The inhibitor and its application method of indole amine 2,3-dioxygenase |
WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
JP2020506895A (en) * | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and / or tryptophan dioxygenase |
US11173145B2 (en) | 2017-01-17 | 2021-11-16 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
JP2020526520A (en) * | 2017-06-30 | 2020-08-31 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Amorphous and crystalline forms of IDO inhibitors |
US11919863B2 (en) | 2017-06-30 | 2024-03-05 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
CN111655264B (en) * | 2017-06-30 | 2023-08-15 | 百时美施贵宝公司 | Substituted quinolinyl cyclohexyl propionamide compounds and improved methods of making the same |
JP2020526504A (en) * | 2017-06-30 | 2020-08-31 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Substituted quinolinyl cyclohexylpropanamide compound and improved method for its production |
KR20200020916A (en) * | 2017-06-30 | 2020-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Amorphous and Crystalline Forms of IDO Inhibitors |
CN111655264A (en) * | 2017-06-30 | 2020-09-11 | 百时美施贵宝公司 | Substituted quinolinylcyclohexylpropanamide compounds and improved processes for their preparation |
JP7315483B2 (en) | 2017-06-30 | 2023-07-26 | ブリストル-マイヤーズ スクイブ カンパニー | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
CN111093651A (en) * | 2017-06-30 | 2020-05-01 | 百时美施贵宝公司 | Amorphous and crystalline forms of IDO inhibitors |
US11236048B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
EP3645008A4 (en) * | 2017-06-30 | 2020-12-09 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation. |
WO2019006292A1 (en) | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation |
CN111093651B (en) * | 2017-06-30 | 2023-06-06 | 百时美施贵宝公司 | Amorphous and crystalline forms of IDO inhibitors |
KR102630575B1 (en) | 2017-06-30 | 2024-01-29 | 브리스톨-마이어스 스큅 컴퍼니 | Amorphous and crystalline forms of IDO inhibitors |
JP2020534336A (en) * | 2017-09-20 | 2020-11-26 | ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co., Ltd. | Polycyclic compounds as IDO inhibitors and / or IDO-HDAC double inhibitors |
WO2019057123A1 (en) | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
US11649212B2 (en) | 2017-10-09 | 2023-05-16 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11180497B2 (en) | 2017-10-18 | 2021-11-23 | Angex Pharmaceutical, Inc. | Cyclic compounds as immunomodulating agents |
US10889568B2 (en) | 2017-10-27 | 2021-01-12 | Boehringer Ingelheim International Gmbh | Inhibitors of TRPC6 |
US10800757B2 (en) | 2017-10-27 | 2020-10-13 | Boehringer Ingelheim International Gmbh | Inhibitors of TRPC6 |
USRE49699E1 (en) | 2017-10-27 | 2023-10-17 | Boehringer Ingelheim International Gmbh | Inhibitors of TRPC6 |
WO2019111107A1 (en) * | 2017-12-05 | 2019-06-13 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3747865A4 (en) * | 2018-01-29 | 2021-10-20 | Beijing InnoCare Pharma Tech Co., Ltd. | Pentafluorosulfanyl-substituted amide compound, preparation method therefor, and medical application thereof |
US11389445B2 (en) | 2018-01-29 | 2022-07-19 | Beijing Innocare Pharma Tech Co., Ltd. | Pentafluorosulfanyl-substituted amide derivatives, preparation methods thereof and medical uses thereof |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11555029B2 (en) | 2018-02-13 | 2023-01-17 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2019170543A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP2021529806A (en) * | 2018-07-06 | 2021-11-04 | ギリアード サイエンシーズ, インコーポレイテッド | Therapeutic heterocyclic compounds |
JP7049519B2 (en) | 2018-07-06 | 2022-04-06 | ギリアード サイエンシーズ, インコーポレイテッド | Therapeutic heterocyclic compounds |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
EP3823604A4 (en) * | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CN110878013B (en) * | 2019-12-13 | 2023-04-28 | 西安瑞联新材料股份有限公司 | Synthesis method of (trans ) -4-vinyl-4' - [ (E) -1-propenyl ] -bicyclohexane |
CN110878013A (en) * | 2019-12-13 | 2020-03-13 | 西安瑞联新材料股份有限公司 | Synthesis method of (trans ) -4-vinyl-4' - [ (E) -1-propenyl ] -bicyclohexane |
EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
WO2022184930A2 (en) | 2021-03-05 | 2022-09-09 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10206893B2 (en) | Immunoregulatory agents | |
US10533014B2 (en) | Immunoregulatory agents | |
US11932601B2 (en) | Immunoregulatory agents | |
US10987322B2 (en) | Immunoregulatory agents | |
BR112017008568B1 (en) | IMMUNORREGULATORY AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15857810 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201702827V Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 2964297 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015342944 Country of ref document: AU Date of ref document: 20151105 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017007782 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2015857810 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015857810 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 252010 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/005729 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15524092 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 40290 Country of ref document: MA Ref document number: 000811-2017 Country of ref document: PE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017524423 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2017/0005218 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 20177015284 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201790998 Country of ref document: EA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15857810 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112017007782 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170413 |